NovaBay Pharmaceuticals (NBY) 10-Q 7 Nov 24 2024 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 05, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-33678
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	68-0454536
Entity Address, Address Line One	2000 Powell Street, Suite 1150
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	899-8800
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	NBY
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		4,885,693
Entity Central Index Key	0001389545
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
us-gaap_AssetsAbstract
Cash and cash equivalents	$ 776	$ 2,924
Accounts receivable, net of allowance for credit losses ($3 at September 30, 2024 and December 31, 2023)	704	680
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($126 and $264 at September 30, 2024 and December 31, 2023, respectively)	473	564
Prepaid expenses and other current assets	326	256
Current assets, discontinued operations	0	2,730
Total current assets	2,279	7,154
Operating lease right-of-use assets	1,042	1,296
Property and equipment, net	61	87
Other assets	495	478
Other assets, discontinued operations	0	19
TOTAL ASSETS	3,877	9,034
Accounts payable	396	906
Accrued liabilities	1,147	1,169
Secured Convertible Notes, net of discounts	0	1,137
Unsecured Convertible Notes, net of discounts	51	0
Operating lease liabilities	390	368
Current liabilities, discontinued operations	0	698
Total current liabilities	1,984	4,278
Warrant liabilities	0	334
Operating lease liabilities-non-current	821	1,108
Total liabilities	2,805	5,720
Commitments and Contingencies
Stockholders’ equity:
Common stock, $0.01 par value; 150,000 shares authorized, 4,885 and 321 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively*	49	3
Additional paid-in capital	183,262	176,210
Accumulated deficit	(182,245)	(174,849)
Total stockholders’ equity	1,072	3,314
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	3,877	9,034
Series B Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	6	275
Series C Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	$ 0	$ 1,675

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) $ in Thousands	3 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Accounts receivable, allowance for doubtful accounts | $	$ 3	$ 3
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments | $	$ 126	$ 264
Preferred stock par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	1
Preferred stock, shares outstanding (in shares)	0	1
Preferred Stock, Shares Issued (in shares)	1
Preferred Stock, Shares Outstanding (in shares)	0	1
Common stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares outstanding (in shares)	4,885,000	321,000
Common stock, shares issued (in shares)	4,885,000	321,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	35
Series B Preferred Stock [Member]
Preferred stock, shares issued (in shares)	1,000	6,000
Preferred stock, shares outstanding (in shares)	1,000	6,000
Preferred Stock, Shares Issued (in shares)	1,000	6,000
Preferred Stock, Shares Outstanding (in shares)	1,000	6,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Sales:
Total sales, net		$ 2,441	$ 2,481	$ 7,472	$ 8,354
Cost of goods sold		848	819	2,493	3,353
Gross profit		1,593	1,662	4,979	5,001
Operating expenses:
Research and development		4	4	32	36
Sales and marketing		947	1,263	3,021	3,674
General and administrative		1,703	1,093	5,611	4,385
Loss on divestiture of subsidiary		0	0	865	0
Total operating expenses		2,654	2,360	9,529	8,095
Operating loss		(1,061)	(698)	(4,550)	(3,094)
Non-cash gain on changes in fair value of warrant liabilities		0	0	114	216
Non-cash (loss) gain on change in fair value of embedded derivative liability		0	0	(18)	40
Accretion of interest and amortization of discounts on convertible notes		(138)	(655)	(871)	(1,156)
Extinguishment of Secured Convertible Notes		(13)	0	(13)	0
Other expense, net		0	0	(549)	(432)
Net loss from continuing operations		(1,212)	(1,353)	(5,887)	(4,426)
Net loss from discontinued operations (Note 18)		0	(404)	(124)	(1,106)
Net loss		(1,212)	(1,757)	(6,011)	(5,532)
Less: Increase to accumulated deficit due to adjustment to common stock warrant exercise price		(1,005)	0	(1,005)	0
Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price		0	0	(380)	(1,996)
Net loss attributable to common stockholders		$ (2,217)	$ (1,757)	$ (7,396)	$ (7,528)
Net loss per share from continuing operations (in dollars per share)	[1]	$ (0.6)	$ (10.1)	$ (3.9)	$ (67.89)
Net loss per share from discontinued operations (in dollars per share)	[1]	0	(3.01)	(0.07)	(11.69)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	[1]	$ (0.6)	$ (13.11)	$ (3.97)	$ (79.58)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares)	[1]	3,710	134	1,863	95
Product [Member]
Sales:
Total sales, net		$ 2,424	$ 2,471	$ 7,435	$ 8,326
Product and Service, Other [Member]
Sales:
Total sales, net		$ 17	$ 10	$ 37	$ 28
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)			3 Months Ended
	May 30, 2024		Sep. 30, 2024
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	35	[1]	35
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Conversion of Series B Preferred Stock to Common Stock [Member]	Preferred Stock [Member] Conversion of Series C Preferred Stock to Common Stock [Member]	Preferred Stock [Member] Employees and Directors [Member]	Preferred Stock [Member] Director [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] The 2022 Warrant Reprice Transaction [Member]	Preferred Stock [Member] May 2023 Warrants [Member]	Preferred Stock [Member] The December 2023 Warrants [Member]	Preferred Stock [Member] March 2024 Warrant [Member]	Preferred Stock [Member]	Common Stock [Member] Conversion of Series B Preferred Stock to Common Stock [Member]		Common Stock [Member] Conversion of Series C Preferred Stock to Common Stock [Member]		Common Stock [Member] Employees and Directors [Member]		Common Stock [Member] Director [Member]		Common Stock [Member] Series B Preferred Stock [Member]	[1]	Common Stock [Member] Series C Preferred Stock [Member]	[1]	Common Stock [Member] The 2022 Warrant Reprice Transaction [Member]	Common Stock [Member] May 2023 Warrants [Member]	[1]	Common Stock [Member] The December 2023 Warrants [Member]	Common Stock [Member] March 2024 Warrant [Member]	Common Stock [Member]		Additional Paid-in Capital [Member] Conversion of Series B Preferred Stock to Common Stock [Member]		Additional Paid-in Capital [Member] Conversion of Series C Preferred Stock to Common Stock [Member]		Additional Paid-in Capital [Member] Employees and Directors [Member]		Additional Paid-in Capital [Member] Director [Member]		Additional Paid-in Capital [Member] Series B Preferred Stock [Member]	[1]	Additional Paid-in Capital [Member] Series C Preferred Stock [Member]	[1]	Additional Paid-in Capital [Member] The 2022 Warrant Reprice Transaction [Member]	Additional Paid-in Capital [Member] May 2023 Warrants [Member]	[1]	Additional Paid-in Capital [Member] The December 2023 Warrants [Member]	Additional Paid-in Capital [Member] March 2024 Warrant [Member]	Additional Paid-in Capital [Member]		Retained Earnings [Member] Conversion of Series B Preferred Stock to Common Stock [Member]	Retained Earnings [Member] Conversion of Series C Preferred Stock to Common Stock [Member]	Retained Earnings [Member] Employees and Directors [Member]	Retained Earnings [Member] Director [Member]	Retained Earnings [Member] Series B Preferred Stock [Member]	Retained Earnings [Member] Series C Preferred Stock [Member]	Retained Earnings [Member] The 2022 Warrant Reprice Transaction [Member]	Retained Earnings [Member] May 2023 Warrants [Member]	Retained Earnings [Member] The December 2023 Warrants [Member]	Retained Earnings [Member] March 2024 Warrant [Member]	Retained Earnings [Member]		Conversion of Series B Preferred Stock to Common Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]	Employees and Directors [Member]	Director [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	The 2022 Warrant Reprice Transaction [Member]	May 2023 Warrants [Member]	The December 2023 Warrants [Member]	March 2024 Warrant [Member]	Total
Balance (in shares) at Dec. 31, 2022											14,000																		58,000	[1]																																										10,554,000
Balance at Dec. 31, 2022											$ 2,973																																					$ 1	[1]											$ 165,732	[1]											$ (158,152)
Net loss											$ 0																		$ 0	[1]																		0	[1]											(1,739)												(1,739)
Stock-based compensation expense related to employee and director stock awards			$ 0													$ 0	[1]																		$ 75	[1]																$ 0												$ 75
Balance (in shares) at Mar. 31, 2023											14,000																		58,000	[1]
Balance at Mar. 31, 2023											$ 2,973																		$ 1	[1]																		165,807	[1]											(159,891)												$ 8,890
Balance (in shares) at Dec. 31, 2022											14,000																		58,000	[1]																																										10,554,000
Balance at Dec. 31, 2022											$ 2,973																																					1	[1]											165,732	[1]											$ (158,152)
Net loss																																																																								(5,532)
Conversion of Preferred Stock to common stock																																																																								995
Balance (in shares) at Sep. 30, 2023											7,000																		186,000	[1]
Balance at Sep. 30, 2023											$ 1,977																		$ 2	[1]																		170,738	[1]											(165,680)												7,037
Balance (in shares) at Mar. 31, 2023											14,000																		58,000	[1]
Balance at Mar. 31, 2023											$ 2,973																		$ 1	[1]																		165,807	[1]											(159,891)												8,890
Net loss											0																		0	[1]																		0	[1]											(2,036)												(2,036)
Conversion of Preferred Stock to common stock (in shares)	3,000	1,000										(54,000)	[1]	(8,000)	[1]
Conversion of Preferred Stock to common stock	$ (121)	$ (728)										$ 0	[1]	$ 0	[1]																$ 121	[1]	$ 728	[1]																$ 0	$ 0											$ 0	$ 0
Adjustment of Series C Preferred Stock conversion price					$ 0	$ 0														$ 0		$ 0																	$ 1,802		$ 194													$ (1,802)	$ (194)											$ 0	$ 0
Stock-based compensation expense related to employee and director stock awards			0													0	[1]																		64	[1]																0												64
Vesting of director restricted stock awards (in shares)				0														0	[1]
Vesting of director restricted stock awards				$ 0														$ 0	[1]																		$ 0	[1]															$ 0												$ 0
Conversion of Preferred Stock to common stock (in shares)	(3,000)	(1,000)										54,000	[1]	8,000	[1]
Modification of common stock warrants											$ 0																		$ 0	[1]																		285	[1]											0												285
Reclassification of May 2023 Warrants								$ 0																	$ 0																			$ 1,360													$ 0												$ 1,360
Balance (in shares) at Jun. 30, 2023											10,000																		120,000	[1]
Balance at Jun. 30, 2023											$ 2,124																		$ 1	[1]																		170,361	[1]											(163,923)												8,563
Net loss																																																												(1,757)												(1,757)
Conversion of Preferred Stock to common stock (in shares)											(3,000)																		66	[1]
Conversion of Preferred Stock to common stock											$ (147)																		$ 1	[1]																		146	[1]
Stock-based compensation expense related to employee and director stock awards																																																62	[1]																							62
Reclassification of embedded derivative liability																																																169	[1]																							169
Conversion of Preferred Stock to common stock (in shares)											3,000																		(66)	[1]
Balance (in shares) at Sep. 30, 2023											7,000																		186,000	[1]
Balance at Sep. 30, 2023											$ 1,977																		$ 2	[1]																		170,738	[1]											(165,680)												7,037
Balance (in shares) at Dec. 31, 2023											7,000																		321,000
Balance at Dec. 31, 2023											$ 1,950																		$ 3																			176,210												(174,849)												3,314
Net loss											0																		0																			0												(3,214)												(3,214)
Conversion of Preferred Stock to common stock (in shares)	(5,000)	0										537,000		57,000
Conversion of Preferred Stock to common stock	$ (231)	$ (234)										$ 5		$ 1																	226		233																	0	0											0	0
Adjustment of Series C Preferred Stock conversion price											$ 0																		$ 0																			380												(380)												0
Stock-based compensation expense related to employee and director stock awards			0													0																			60																	0												60
Conversion of Preferred Stock to common stock (in shares)	5,000	0										(537,000)		(57,000)
Balance (in shares) at Mar. 31, 2024											2,000																		915,000
Balance at Mar. 31, 2024											$ 1,485																		$ 9																			177,109												(178,443)												160
Balance (in shares) at Dec. 31, 2023											7,000																		321,000
Balance at Dec. 31, 2023											$ 1,950																		$ 3																			176,210												(174,849)												3,314
Net loss																																																																								(6,011)
Conversion of Preferred Stock to common stock																																																																								1,944
Balance (in shares) at Sep. 30, 2024											1,000																		4,885,000
Balance at Sep. 30, 2024											$ 6																		$ 49																			183,262												(182,245)												1,072
Balance (in shares) at Mar. 31, 2024											2,000																		915,000
Balance at Mar. 31, 2024											$ 1,485																		$ 9																			177,109												(178,443)												160
Net loss											$ 0																		$ 0																			0												(1,585)												(1,585)
Conversion of Preferred Stock to common stock (in shares)	0	(1,000)										88,000		148,000
Conversion of Preferred Stock to common stock	$ (37)	$ (1,442)										$ 1		$ 1																	$ 36		$ 1,441																	$ 0	$ 0											$ 0	$ 0
Stock-based compensation expense related to employee and director stock awards			$ 0													$ 0																			$ 55																	$ 0												$ 55
Modification of common stock warrants in connection with 2024 Warrant Reprice Transaction							$ 0																	$ 0																			$ 69													$ 0												$ 69
Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs (in shares)											0																		90,000
Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs											$ 0																		$ 1																			129												0												130
Reclassification of Warrants from liability									$ 0	$ 0																	$ 0	$ 0																		$ 212	$ 100											$ 0	$ 0											$ 212	$ 100
Reclassification of embedded derivative liability											$ 0																		$ 0																			242												0												242
Shares issued for 35:1 reverse stock split due to rounding feature (in shares)											0																		107,000
Shares issued for 35:1 reverse stock split due to rounding feature											$ 0																		$ 1																			(1)												0												0
Vesting of director restricted stock awards (in shares)				0														0
Vesting of director restricted stock awards				$ 0														$ 0																			$ 0																$ 0												$ 0
Conversion of Preferred Stock to common stock (in shares)	0	1,000										(88,000)		(148,000)
Balance (in shares) at Jun. 30, 2024											1,000																		1,348,000
Balance at Jun. 30, 2024											$ 6																		$ 13																			179,392												(180,028)												(617)
Net loss																																																												(1,212)												(1,212)
Stock-based compensation expense related to employee and director stock awards																																																22																								22
Modification of common stock warrants in connection with 2024 Warrant Reprice Transaction																																																1,005												(1,005)
Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs (in shares)																													2,042,000
Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs																													$ 21																																											21
Issuance of common stock and pre-funded warrants in an underwritten registered direct offering, net of issuance cost (in shares)																													1,495,000
Issuance of common stock and pre-funded warrants in an underwritten registered direct offering, net of issuance cost																													$ 15																			2,843																								2,858
Balance (in shares) at Sep. 30, 2024											1,000																		4,885,000
Balance at Sep. 30, 2024											$ 6																		$ 49																			$ 183,262												$ (182,245)												$ 1,072
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) - Reverse Stock Split [Member]			3 Months Ended
	May 30, 2024	[1]	Sep. 30, 2024
Stockholders' Equity Note, Stock Split, Conversion Ratio	35		35
Stockholders' Equity Note, Stock Split, Conversion Ratio	35		35
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities:
Net loss	$ (6,011)	$ (5,532)
Net loss from discontinued operations	124	1,106
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	32	39
Stock-based compensation expense related to employee and director stock awards	137	201
Loss on divestiture of subsidiary	865	0
Non-cash expense incurred to obtain consent of Secured Convertible Note holders	368	0
Modification of common stock warrants, included in Other expense, net	69	285
Non-cash gain on changes in fair value of warrant liabilities	(114)	(216)
Non-cash loss (gain) on changes in fair value of embedded derivative liability	18	(40)
Non-cash right-of-use amortization	254	222
Accretion of interest and amortization of debt discounts on convertible notes	871	1,119
Changes in operating assets and liabilities:
Accounts receivable	(24)	913
Inventory	83	(195)
Prepaid expenses and other current assets	(70)	82
Other assets	(16)	(10)
Accounts payable and accrued liabilities	(532)	(1,289)
Operating lease liabilities	(265)	(224)
Net cash used in operating activities, continuing operations	(4,211)	(3,539)
Investing activities:
Proceeds from divestiture of subsidiary	1,070	0
Purchases of property and equipment	(6)	(16)
Net cash provided by (used in) investing activities, continuing operations	1,064	(16)
Financing activities:
Payments on Secured Convertible Notes	(1,990)	(770)
Debt issuance cost	(115)	(294)
Net cash provided by financing activities, continuing operations	1,000	1,936
Net decrease in cash, cash equivalents, and restricted cash, continuing operations	(2,147)	(1,619)
Net decrease in cash and cash equivalents, discontinued operations	(206)	(279)
Net decrease in cash, cash equivalents, and restricted cash, consolidated	(2,353)	(1,898)
Cash, cash equivalents and restricted cash, beginning of year, consolidated	3,606	5,846
Less: Cash and cash equivalents of discontinued operations, end of period	0	(293)
Cash, cash equivalents and restricted cash of continuing operations, end of period	1,253	3,655
Supplemental disclosure of cash flow information:
Interest paid in continuing operations	147	174
Interest paid in discontinued operations	0	15
Supplemental disclosure of non-cash information:
Conversion of Preferred Stock to common stock	1,944	995
Down round feature adjustments related to Preferred Stock	380	1,996
Down round feature adjustments related to common stock warrants	1,005	0
Issuance of embedded derivative liability in conjunction with Unsecured Convertible Notes	224	0
Warrant liabilities transferred to equity	242	169
Convertible Notes and May 2023 Warrants [Member]
Financing activities:
Proceeds from issuance of Secured Convertible Notes and May 2023 Warrants, net of discounts	0	3,000
Underwritten Registered Direct Offering [Member]
Financing activities:
Proceeds from issuance of common stock and pre-funded warrants in an underwritten registered direct offering, net of issuance costs	2,858	0
Warrants and Pre-funded Warrants [Member]
Financing activities:
Proceeds from Warrant Exercise	247	0
Warrant Liability [Member]
Supplemental disclosure of non-cash information:
Warrant liabilities transferred to equity	$ 312	$ 1,360

Note 1 - Organization

Note 1 - Organization	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	ORGANIZATION NovaBay Pharmaceuticals, Inc. (“ our we us Company FDA We also manufacture and sell our proprietary form of hypochlorous acid for the wound care market through our NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries. The Company currently sells these products through distributors. Through our former subsidiary DERMAdoctor, LLC (“ DERMAdoctor DERMAdoctor Divestiture The Company operated in principally two The Company was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc. It had no operations until July 1, 2002, on which date it acquired all of the operating assets of NovaCal Pharmaceuticals, LLC, a California limited liability company. In February 2007, the Company changed its name from NovaCal Pharmaceuticals, Inc. to NovaBay Pharmaceuticals, Inc. In June 2010, the Company changed the state in which it was incorporated (the “ Reincorporation Effective May 30, 2024, the Company effected a 1-for-35 reverse split of our outstanding common stock (“ Reverse Stock Split Potential Asset Sale Transaction and Dissolution On September 19, 2024, the Company entered into an Asset Purchase Agreement (the “ Original Purchase Agreement PRN Avenova Assets Asset Sale Transaction APA Amendment Purchase Agreement Bridge Loan The Asset Sale Transaction would constitute substantially all of the Company’s revenue generating and operating assets; however, PRN would not purchase any of the Company’s other products and assets, including those that relate to the Company’s wound care, urology or dermatology businesses. The Company’s board of directors (the “ Board Plan of Dissolution Dissolution The Company has called a special meeting of stockholders (the “ Special Meeting On October 29, 2024, the Company announced that the Board determined that an unsolicited and non-binding acquisition proposal from Refresh Acquisitions BidCo LLC (“ Refresh Refresh Unsolicited Offer On November 5, 2024, the Company and PRN entered into the APA Amendment to the Original Purchase Agreement. The APA Amendment provides for the following primary revisions to the Original Purchase Agreement: (i) an increase in the base purchase price to $11.5 million from $9.5 million; (ii) the removal of debt financing contingencies and related PRN representations, while adding a new PRN representation that it has sufficient funding for the $11.5 million base purchase price; (ii) PRN providing the Company with the Bridge Loan; and (iv) PRN providing the Company with an equity funding commitment letter (the “ Equity Commitment Letter Revised PRN Transaction Terms On November 5, 2024, the Company entered into the Bridge Loan that provides for the Company to receive a secured loan of up to $1.0 million from PRN as the lender that will be funded in two tranches of $0.5 million each upon the Company providing written notice to PRN on or after November 22, 2024 and on or after December 6, 2024. The amounts borrowed under the Bridge Loan are required to be used for working capital purposes, will bear interest at a rate of 10% per annum and be secured by all of the Company’s assets as collateral. The Bridge Loan is a short term secured loan that is to be repaid upon the earlier of the closing of the Asset Sale Transaction (to be repaid from the purchase price), immediately upon termination of the Purchase Agreement or February 28, 2025. For more information on the Asset Sale Transaction (including the Revised PRN Transaction Terms, the APA Amendment and the Bridge Loan), the Refresh Unsolicited Offer and the Dissolution, please see Note 19, “Subsequent Events,” the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission (the “ SEC Special Meeting Proxy Statement Discontinued Operations On March 25, 2024, the Company completed the DERMAdoctor Divestiture for an aggregate sale price of $1.1 million. The Company recognized a loss on the DERMAdoctor Divestiture amounting to $0.9 million in the three-month period ended March 31, 2024, which is recorded in loss on divestiture of subsidiary in the unaudited condensed consolidated statements of operations. In connection with the DERMAdoctor Divestiture, the Company entered into Transition Services Agreement with New Age Investments, LLC to provide for a customary and orderly transition of the business, including warehousing services provided by New Age Investments, LLC and fulfillment services provided by the Company, which has been included in continuing operations in subsequent periods since entering into the Transition Services Agreement. Going Concern The Company has sustained operating losses for the majority of its corporate history and expects that its 2024 expenses will exceed its 2024 revenues. Additionally, the Company expects to continue incurring operating losses and negative cash flows. Accordingly, the Company has determined that its planned operations raise substantial doubt about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Additionally, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control that impact the broader economy such as periods of inflation, supply chain issues, global pandemics and international conflicts (e.g., the conflicts between Israel and Hamas, Russia and Ukraine, and China and Taiwan). On September 16, 2024, the Board unanimously approved the Asset Sale Transaction and the Dissolution, both of which are subject to the approval of the Company’s stockholders. On November 5, 2024, the Company entered into the APA Amendment that provides for, among other terms, an increase in the base purchase price to $11.5 million from $9.5 million and for PRN to provide the Company with the Bridge Loan, as further described below under Note 19, “Subsequent Events.” The Company is holding the Special Meeting on November 22, 2024 to obtain stockholder approval of the Asset Sale Transaction and the Dissolution, pursuant to the Special Meeting Proxy Statement. To address the Company’s current liquidity and near term capital needs, the Company has and continues to evaluate different plans and strategic transactions to fund operations, including: (1) raising additional capital through debt and equity financings or from other sources; (2) reducing spending on operations, including reducing spending on one or more of its sales and marketing programs or restructuring operations to change its overhead structure; and/or (3) the divestiture of certain business or product lines and related assets such as the Asset Sale Transaction and the DERMAdoctor Divestiture. If the Asset Sale Transaction and/or the Dissolution are not completed, we will continue our corporate existence and the Board will continue to explore its options to secure immediate funding for ongoing operations due to significantly reduced available capital and liquidity, the strategic alternatives available to the Company, including returning capital to stockholders or, to the extent any funding or other viable alternatives are not available or if there is not sufficient capital remaining at the time to fund operations, then the Company may need to file for bankruptcy protection or commence a similar state law proceeding. In connection with such strategic options, the Company may issue securities, including common stock, preferred stock, convertible debt securities and warrants through additional private placement transactions or registered public offerings, which may require the filing of a Form S-1 or Form S-3 registration statement with the SEC. While the Company believes that the proceeds from the 2024 Public Offering (as defined in Note 9, “Financing Activities”), the 2024 Warrant Reprice Transaction (as defined in Note 9, “Financing Activities”) and the DERMAdoctor Divestiture improved the Company’s liquidity for the first nine months of 2024, there is no assurance that the Company will be successful in completing the Asset Sale Transaction and/or the Dissolution or otherwise executing on alternative capital raising strategies at levels necessary to address the Company’s ongoing and future cash flow and liquidity needs. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. If the Company’s stockholders approve the Dissolution, the Company would consider liquidation to be imminent and apply the liquidation basis of accounting pursuant to the accounting principles generally accepted in the United States (“ U.S. GAAP

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and are expressed in U.S. dollars. In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position and operating results. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its former wholly-owned subsidiary, DERMAdoctor, as of and for the nine months ended September 30, 2024. All significant intercompany balances and transactions have been eliminated in consolidation. As of March 25, 2024, the Company divested its wholly-owned subsidiary pursuant to the DERMAdoctor Divestiture. The financial results for DERMAdoctor have been presented as discontinued operations in the accompanying condensed consolidated financial statements. For the nine months ended September 30, 2024, all gains and losses on disposition, along with the sales, costs and expenses attributable to discontinued operations, have been aggregated in the captions entitled “Loss on divestiture of subsidiary” and “Net loss from discontinued operations” in our unaudited condensed consolidated statements of operations. Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these unaudited condensed consolidated financial statements to conform to current period classifications. The prior year amounts have been modified in these unaudited condensed consolidated financial statements to properly report amounts under current operations and discontinued operations (see Note 18, “Divestiture and Discontinued Operations”). Further, certain prior period operating lease balances on the Condensed Consolidated Statements of Cash Flows originally reported within changes in “Operating lease right-of-use assets” are now within “Non-cash right-of-use amortization” to conform to the current year presentation. These changes had no impact on the Company's net decrease in case, cash equivalents, and restricted cash in the prior year nor any of the subtotal changes of cash from operating, investing, or financing activities. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, contract liabilities related to product sales such as product returns, assumptions for valuing warrants, assumptions for valuing derivative liabilities, the fair value of contingent consideration, intangible assets, goodwill, stock-based compensation, income taxes and other contingencies. These estimates are based on management’s best estimates and judgment. Actual results may differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on management’s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. Unaudited Condensed Consolidated Interim Financial Information The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation. The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The unaudited condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 26, 2024 and amended on March 29, 2024 (collectively, the “ 2023 Annual Report Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of September 30, 2024 and December 31, 2023, the Company’s cash and cash equivalents were held in a major financial institution in the United States. The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands): September 30, December 31, 2024 2023 Cash and cash equivalents $ 776 $ 3,130 Cash and cash equivalents, discontinued operations — (206 ) Restricted cash included in other assets 477 476 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 1,253 $ 3,400 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. The Company has a significant amount of its cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. During the three and nine months ended September 30, 2024 and 2023, revenues from significant product categories were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Avenova Spray $ 2,170 $ 2,064 $ 6,391 $ 5,759 NeutroPhase — — — 1,043 Other products 254 407 1,044 1,524 Total product revenue, net 2,424 2,471 7,435 8,326 Other revenue, net 17 10 37 28 Total sales, net $ 2,441 $ 2,481 $ 7,472 $ 8,354 During the three and nine months ended September 30, 2024 and 2023, revenues were derived primarily from sales of Avenova branded products, directly to consumers through Amazon.com and Avenova.com. Sales of Avenova Spray via Amazon comprised 73% and 66% of total Avenova Spray net revenue during the three months ended September 30, 2024 and 2023, respectively. Sales of Avenova Spray via Amazon comprised 74% and 68% of total Avenova Spray net revenue during the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and December 31, 2023, accounts receivable from continuing operations from our major distribution partners and major retailers greater than 10% were as follows: September 30, December 31, Major distribution partner 2024 2023 Major U.S. Retailer A 43 % 22 % Avenova Spray Pharmacy Distributor A 31 % 14 % Chongqing Pioneer Pharma Holdings Limited * % 36 % * Less than 10% The Company relies on one Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ ASC Fair Value Measurements and Disclosures Level 1 – quoted prices in active markets for identical assets or liabilities; Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. See additional information in Note 3, “Fair Value Measurements”. Allowance for Credit Losses The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company’s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand as of September 30, 2024 and December 31, 2023. Inventory Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. The Company utilizes a contract manufacturer to produce its products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At September 30, 2024 and December 31, 2023, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $126 thousand and $264 thousand, respectively. Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred. Business Combinations, Goodwill and Indefinite-Lived Intangible Assets We account for Business Combinations Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Goodwill is evaluated for impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary. If it is determined, based on qualitative factors, that the fair value of the reporting unit may more likely than not be less than carrying amount, or if significant adverse changes in the Company’s future financial performance occur that could materially impact fair value, a quantitative goodwill impairment test would be required. Additionally, management can elect to forgo the qualitative assessment and perform the quantitative test. If the qualitative assessment indicates that the quantitative analysis should be performed, or if management elects to bypass a qualitative assessment, the Company then evaluates goodwill for impairment by comparing the fair value of the reporting unit to its carrying amount, including goodwill. The quantitative assessment for goodwill requires management to estimate the fair value of the Company’s reporting units using either an income or market approach or a combination thereof. Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Company’s cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. The Company did not Valuation of Contingent Consideration Resulting from a Business Combination In connection with the DERMAdoctor acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the condensed consolidated statements of operations. The DERMAdoctor acquisition milestone events consisted of financial targets for calendar years 2022 and 2023 which were not met. As a result, the liability recorded for potential earn out payments in the Company’s condensed consolidated balance sheets was zero Long-Lived Assets The Company’s intangible assets that do not have indefinite lives, primarily trade secrets and product formulations, are amortized over their estimated useful lives. All of the Company’s intangible assets subject to amortization and other long-lived assets, are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment The Company did not Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received. The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not applied. Leases include variable components (e.g., common area maintenance) that are paid separately from the monthly base payment based on actual costs incurred and therefore were not included in the right-of-use assets and lease liability but are reflected as an expense in the period incurred. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheets as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. Common Stock Warrants The Company accounts for the issuance of common stock purchase warrants issued in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, the Company also classifies as liabilities any warrants during the period which the shares underlying the contract are subject to stockholder approval before the warrant can be exercised. For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions” and Note 11, “Common Stock Warrants”, subheading “Summary of Common Stock Warrant Liabilities”. Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. See Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”. Preferred Stock Terms of the Company’s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 12, “Stockholders’ Equity”). The applicable Ratchet provisions of the Company’s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend was measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). These fair values were determined using the Black Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See also Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”. Revenue Recognition The Company’s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is recognized in accordance with the amount of consideration which the Company expects to receive. Revenue generated from end consumers through third-party online retailers, such as Amazon, as well as the Company’s web store (Avenova.com) is recognized on a “sell-through” basis when control of the goods is transferred to the consumer, which generally occurs upon delivery of the products to the party fulfilling the consumer’s order. Revenue is recorded net of any discounts and estimates for refunds and product returns. Fees paid to third-party online retailers and fulfillment parties are recorded as incurred in the Company’s condensed consolidated statements of operations. Fulfillment and shipping and handling fees are recorded as product cost of goods sold. Selling commissions and advertising and promotion fees are recorded as sales and marketing expenses. Revenue generated through major pharmacy distributors is recognized on a “sell-in” basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for products sold is typically due 60 days after delivery to the distributor. Revenue generated from end consumers through the Company’s partner pharmacies is recognized on a “sell-through” basis when control of the goods is transferred to the consumer. Revenue generated from other retailers is recognized on a “sell-through” basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third-party carrier who is delivering the products to the retailer. The Company defers recognition for pre-payments until the Company’s performance obligations are satisfied. Cost of Goods Sold Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, third-party fulfillment fees, and other costs associated with products sold. Cost of goods sold also includes any necessary allowances for excess and obsolete inventory as well as lower of cost and estimated net realizable value. Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities. Patent Costs Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations. Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $0.1 million and $0.3 million for the three months ended September 30, 2024 and 2023, respectively. Advertising expenses were $0.5 million and $0.8 million for the nine months ended September 30, 2024 and 2023, respectively. Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“ RSUs Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized. Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“ EPS Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. For the three and nine months ended September 30, 2024 and 2023, the Series B Preferred Stock and Series C Preferred Stock (both as defined below) were excluded from the computation of diluted net loss per share as their inclusion on an “if converted” basis would have been anti-dilutive. The Series B Preferred Stock and Series C Preferred Stock were considered anti-dilutive because such securities did not have a contractual obligation to participate in losses of the Company. The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Balance at September 30, 2024* 2023* Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “ Series B Preferred Stock 15,065 135,300 Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “ Series C Preferred Stock — 24,134 Stock options 6,893 4,240 Stock warrants 10,836,275 210,929 10,858,233 374,603 * After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024. Recent Accounting Pronouncements For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, “Summary of Significant Accounting Policies” included in our 2023 Annual Report. The Company continues to evaluate the potential impact of adopting the new accounting guidance on its consolidated financial position, results of operations and cash flows.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. FAIR VALUE MEASUREMENTS The following table presents the Company’s financial instruments measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable September Items Inputs Inputs 30, 2024 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 477 $ 477 $ — $ — Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable December Items Inputs Inputs 31, 2023 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 476 $ 476 $ — $ — Liabilities Warrant liabilities $ 334 $ — $ 334 $ — The Company’s restricted cash held as certificates of deposit are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The Secured Convertible Notes and Unsecured Convertible Notes (see Note 10, “Convertible Notes”) are carried at proceeds, net of discounts, which management believes approximates fair value. As a result of certain call and put options within the Secured Convertible Notes and Unsecured Convertible Notes, the Company recorded an embedded derivative liability on its condensed consolidated balance sheets with a corresponding debt discount which is netted against the face value of the Secured Convertible Notes and Unsecured Convertible Notes. The fair value of the embedded derivatives were calculated using the Black Scholes valuation model using Level 2 inputs of the fair value hierarchy. The fair value of the December 2023 Warrants issued in conjunction with the 2023 Warrant Reprice Transaction as well as the accounting for the warrant amendment and preferred stock conversion price adjustments that resulted from the 2023 Warrant Reprice Transaction were classified within Level 2. See Note 11, “Common Stock Warrants”, subheading “Summary of Common Stock Warrant Liabilities”, for a reconciliation of the beginning and ending balances for the warrant liabilities measured at fair value on a recurring basis using significant other observable inputs (Level 2) during the three and nine months ended September 30, 2024 and 2023. There were no transfers in or out of Level 1, Level 2 or Level 3 assets and liabilities for the three and nine months ended September 30, 2024 and 2023. Black Scholes Valuation Models and Assumptions The Company utilizes a Black Scholes model for various valuations as outlined throughout this report. The following tables summarize the assumptions utilized for valuations impacting results for the periods reported. See also Note 13, “Equity-Based Compensation” for related Black Scholes valuation assumptions. Warrant Liabilities Various of the Company’s warrants have been subject to stockholder approval upon issuance or amendment and prior to exercise. Warrants requiring stockholder approval are recorded as a liability at fair value upon issuance or amendment and continue to be recorded as a liability at fair value at each reporting date until stockholder approval occurs at which time they are transferred to stockholders’ equity at their fair value on the date of approval. Fair value was determined using a Black Scholes model as outlined below. See Note 11, “Common Stock Warrants” for additional information and the definitions of the Company’s warrants. May 2023 Warrants May 2023 Warrants December 2023 Warrants December 2023 Warrants Measurement event Issuance Stockholder Approval Reporting Date Stockholder Approval Date May 1, 2023 June 9, 2023 December 31, 2023 May 28, 2024 Total Value $1.6 million $1.4 million $0.3 million $0.2 million Gain (Loss) not applicable $0.2 million $56 thousand $(51 thousand) Assumptions: Exercise price $ 45.50 $ 45.50 $ 8.75 $ 8.75 Market price $ 25.20 (a) $ 23.80 $ 7.14 $ 4.94 Volatility 80.1 % 77.6 % 79.3 % 83.9 % Risk-free rate 3.60 - 4.04 % 3.92 - 4.59 % 3.85 % 4.56 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % Term (years) 2.1 - 5.1 2.0 - 5.0 5.5 5.1 March March 2024 2024 Warrant Warrant Measurement event Reporting Date Stockholder Approval Date March 31, 2024 May 28, 2024 Total Value $0.1 million $0.1 million Gain (Loss) $21 thousand $(28 thousand) Assumptions: Exercise price $ 4.90 $ 4.90 Market price $ 3.66 $ 4.94 Volatility 86.9 % 83.9 % Risk-free rate 4.21 % 4.56 % Dividend yield 0.0 % 0.0 % Term (years) 5.5 5.3 (a) Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. Warrant Modifications Amendments to warrant terms are recorded as a non-cash gain (or loss) on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. Fair value was determined using a Black Scholes model as outlined below. July 2020, November 2021, September 2022 & November 2022 Warrants Measurement event Prior to amendment After amendment Date April 27, 2023 April 27, 2023 Total Value $0.3 million $0.5 million Loss not applicable $0.2 million Assumptions: Exercise price $ 220.50 $ 52.50 Market price $ 25.20 (a) $ 25.20 (a) Volatility 80.1 % 80.1 % Risk-free rate 3.59 - 4.73 % 3.59 - 4.73 % Dividend yield 0.0 % 0.0 % Term (years) 1.1 - 5.6 1.1 - 5.6 May 2023 Warrants Measurement event Prior to amendment After amendment Date December 21, 2023 December 21, 2023 Total Value $56 thousand $0.2 million Loss not applicable $0.1 million Assumptions: Exercise price $ 45.50 $ 8.75 Market price $ 8.07 $ 8.07 Volatility 79.3 % 79.3 % Risk-free rate 3.92 - 4.62 % 3.92 - 4.62 % Dividend yield 0.0 % 0.0 % Term (years) 1.5 - 4.5 1.5 - 4.5 September 2022, November 2022, and May 2023 Warrants Measurement event Prior to amendment After amendment Date June 14, 2024 June 14, 2024 Total Value $66 thousand $0.1 million Loss not applicable $70 thousand Assumptions: Exercise price $ 8.75-52.50 $ 2.50 Market price $ 2.51 $ 2.51 Volatility 89.3 % 89.3 % Risk-free rate 4.27 - 5.08 % 4.27 - 5.08 % Dividend yield 0.0 % 0.0 % Term (years) 1.0 - 4.4 1.0 - 4.4 (a) Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. Warrant Down Round Feature Adjustment Terms of the Company’s outstanding 2024 July Warrants included a down round feature adjustment whereby the applicable exercise price was automatically adjusted (see Note 9, “Financing Activities”). When the exercise price was adjusted, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend is measured as the difference between (1) the fair value of the 2024 July Warrants immediately prior to the conversion price adjustment and (2) the fair value of the 2024 July Warrants immediately after the conversion price adjustment. Fair value was determined using a Black Scholes model, as outlined below. Series F-1 Measurement event Prior to adjustment After adjustment Date September 27, 2024 September 27, 2024 Total value $1.7 million $1.9 million Deemed dividend not applicable $0.2 million Assumptions: Exercise price $ 1.10 $ 0.66 Market price $ 0.71 $ 0.71 Volatility 97.1 % 97.1 % Risk-free rate 3.55 % 3.55 % Dividend yield 0.0 % 0.0 % Term (in years) 4.84 4.84 Series F-2 Measurement event Prior to adjustment After adjustment Date September 27, 2024 September 27, 2024 Total value $0.2 million $0.6 million Deemed dividend not applicable $0.4 million Assumptions: Exercise price $ 1.10 $ 0.66 Market price $ 0.71 $ 0.71 Volatility 97.1 % 97.1 % Risk-free rate 4.64 % 4.64 % Dividend yield 0.0 % 0.0 % Term (in years) 0.34 0.34 Series F-3 Measurement event Prior to adjustment After adjustment Date September 27, 2024 September 27, 2024 Total value $0.6 million $1.0 million Deemed dividend not applicable $0.4 million Assumptions: Exercise price $ 1.10 $ 0.66 Market price $ 0.71 $ 0.71 Volatility 97.1 % 97.1 % Risk-free rate 4.10 % 4.10 % Dividend yield 0.0 % 0.0 % Term (in years) 0.84 0.84 Preferred Stock Conversion Price Adjustments Terms of the Company’s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (see Note 12, “Stockholders’ Equity”). The applicable Ratchet provisions of the Company’s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend is measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). Fair value was determined using a Black Scholes model as outlined below. Series B & C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date April 27, 2023 April 27, 2023 Total value (b) $9.6 million $11.6 million Deemed dividend not applicable $2.0 million Assumptions: Exercise price $ 220.50 $ 45.50 Market price $ 25.20 (a) $ 25.20 (a) Volatility 80.1 % 80.1 % Risk-free rate 4.91 % 4.91 % Dividend yield 0.0 % 0.0 % Term (in years) 0.8 0.8 Series B & C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date December 21, 2023 December 21, 2023 Total value (b) $1.7 million $6.8 million Deemed dividend not applicable $5.1 million Assumptions: Exercise price $ 45.50 $ 8.75 Market price $ 8.07 $ 8.07 Volatility 79.3 % 79.3 % Risk-free rate 5.43 % 5.43 % Dividend yield 0.0 % 0.0 % Term (years) 0.3 0.3 Series C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date March 24, 2024 March 24, 2024 Total value (b) $0.5 million $0.9 million Deemed dividend not applicable $0.4 million Assumptions: Exercise price $ 8.75 $ 4.90 Market price $ 4.77 $ 4.77 Volatility 79.9 % 79.9 % Risk-free rate 5.51 % 5.51 % Dividend yield 0.0 % 0.0 % Term (in years) 0.1 0.1 (a) Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. (b) Includes value of incremental shares underlying preferred stock and adjusted for probability of occurrence. Bifurcatable Derivatives Upon issuance in March 2024, the Unsecured Convertible Notes contained a lender’s conversion option which represented an embedded call option requiring bifurcation as an embedded derivative liability at fair value (see Note 10, “Convertible Notes” for additional discussion). Fair value was determined using a Black Scholes model as outlined below. Unsecured Convertible Notes derivative Unsecured Convertible Notes derivative Measurement event Issuance Shareholder Approval Date March 25, 2024 May 28, 2024 Total value $0.2 million $0.2 million Gain (Loss) not applicable $(82 thousand) Assumptions: Exercise price $ 4.90 $ 4.90 Market price $ 4.51 $ 4.94 Volatility 86.9 % 83.9 % Risk-free rate 4.54 % 4.94 % Dividend yield 0.0 % 0.0 % Term (years) 2.0 1.8 Upon issuance in May 2023, the Secured Convertible Notes contained a lender’s conversion option which represented an embedded call option requiring bifurcation as an embedded derivative liability at fair value (see Note 10, “Convertible Notes” for additional discussion). Fair value was determined using a Black Scholes model as outlined below. Secured Convertible Notes derivative Secured Convertible Notes derivative Measurement event Issuance Shareholder Approval Date April 27, 2023 June 9, 2023 Total value (b) $0.2 million $0.2 million Gain not applicable $40 thousand Assumptions: Exercise price $ 45.50 $ 45.50 Market price $ 25.20 (a) $ 23.80 Volatility 80.1 % 76.9 % Risk-free rate 4.88 % 5.41 % Dividend yield 0.0 % 0.0 % Term (years) 0.8 0.7 (a) Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above. (b) Adjusted for probability of occurrence.

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following (in thousands): September 30, December 31, 2024 2023 Prepaid insurance $ 73 $ 66 Prepaid dues and subscriptions 63 85 Prepaid taxes 49 83 Prepaid inventory 25 73 Other 116 81 Prepaid expenses from discontinued operations — (132 ) Total prepaid expenses and other current assets $ 326 $ 256

Note 5 - Inventory

Note 5 - Inventory	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. INVENTORY Inventory consisted of the following (in thousands): September 30, December 31, 2024 2023 Raw materials and supplies $ 144 $ 1,027 Finished goods 455 2,477 Less: Reserve for excess and obsolete inventory (126 ) (627 ) Inventory, net of reserves, from discontinued operations — (2,313 ) Total inventory, net $ 473 $ 564

Note 6 - Property and Equipment

Note 6 - Property and Equipment	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. PROPERTY AND EQUIPMENT Property and equipment consisted of the following (in thousands): September 30, December 31, 2024 2023 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 414 431 Leasehold improvements 152 152 Total property and equipment, at cost 743 760 Less: accumulated depreciation (682 ) (673 ) Total property and equipment, net $ 61 $ 87 Depreciation expense related to continuing operations was $9 thousand and $13 thousand for the three months ended September 30, 2024 and 2023, respectively, and $32 thousand and $39 thousand for the nine months ended September 30, 2024 and 2023, respectively. The Company recorded no no

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7. ACCRUED LIABILITIES Accrued liabilities consisted of the following (in thousands): September 30, December 31, 2024 2023 Contract liabilities (see Note 14) $ 751 $ 946 Employee payroll and benefits 288 341 Other 108 229 Accrued liabilities from discontinued operations — (347 ) Total accrued liabilities $ 1,147 $ 1,169

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 8. COMMITMENTS AND CONTINGENCIES Indemnification Agreements As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future payments. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, it has not recorded any liabilities for these agreements as of September 30, 2024 or December 31, 2023. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other entities, typically its clinical research organizations, investigators, clinical sites, suppliers, and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third party with respect to its products. The term of these indemnification agreements is generally perpetual. The potential future payments the Company could be required to make under these indemnification agreements is unlimited. Historically, costs related to these indemnification provisions have been immaterial. The Company also maintains various liability insurance policies that limit its exposure. As a result, it believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of September 30, 2024 or December 31, 2023. Legal Matters From time to time, the Company is subject to various legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business. The ultimate outcome of any litigation or other legal dispute is uncertain. When a loss related to a legal proceeding or claim is probable and reasonably estimable, the Company accrues its best estimate for the ultimate resolution of the matter. If one or more legal matters are resolved against the Company in a reporting period for an amount above expectations, the Company’s financial condition and operating results for that period may be adversely affected. As of September 30, 2024 and December 31, 2023, there were no legal matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Company’s financial position, results of operations or cash flows. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention and other factors. The Company cannot provide assurance that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against it in the future, and these matters could relate to prior, current, or future transactions or events. Leases The Company leases office space for its corporate headquarters located in Emeryville, California. The current lease term expires on July 31, 2027. Lease costs for the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease – expense $ 100 $ 100 $ 300 $ 300 Operating lease from discontinued operations – expense — 30 — 91 Operating lease – included in operating cash flow 117 113 310 301 Operating lease from discontinued operations – included in operating cash flow — 33 — 97 The Company has measured its operating lease liabilities as the present value of minimum lease payments using its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate for operating leases from continuing operations are summarized as follows: September 30, 2024 September 30, 2023 Weighted-average remaining lease term (in years) 2.8 3.6 Weighted-average discount rate 5 % 5 % Future lease payments under non-cancelable leases as of September 30, 2024 were as follows (in thousands): 2024 $ 117 2025 439 2026 444 2027 290 Total future minimum lease payments 1,290 Less: Imputed interest (79 ) Total $ 1,211 Reported as: Operating lease liability $ 390 Operating lease liability – non-current 821 Total $ 1,211

Note 9 - Financing Activities

Note 9 - Financing Activities	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 9. FINANCING ACTIVITIES See Notes 2, Summary of Significant Accounting Policies ; 3, Fair Value Measurements ; 10, Convertible Notes ; 11, Common Stock Warrants and 12, Stockholders Equity for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. 2024 Public Offering On July 26, 2024, the Company entered into an underwriting agreement (the “ Underwriting Agreement Underwriter 2024 Public Offering July 2024 Pre-Funded Warrants Series F-1 Warrants Series F-2 Warrants Series F-3 Warrants July 2024 Warrants The Series F-1 Warrants had an exercise price of $1.10 per share at issuance, were exercisable immediately upon issuance, and will expire on the five six one The July 2024 Warrants include a down round feature adjustment where the exercise price was automatically reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the volume weighted average prices for the five (5) trading days immediately preceding the date that is sixty calendar days after issuance of the July 2024 Warrants as applicable. Such down round feature adjustment was triggered on September 27, 2024, resulting in a reduced exercise price of $0.66. The exercise price and number of shares of common stock issuable upon exercise of the July 2024 Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price. Subject to limited exceptions, a holder may not exercise any portion of its July 2024 Warrants to the extent that the holder would beneficially own more than 4.99% (or, at the election of the holder prior to the date of issuance, 9.99%) of the Company’s outstanding common stock after exercise. In addition, the Company granted the Underwriter a 45-day option to purchase up to 477,272 additional shares of common stock and/or 477,272 Series F-1 Warrants to purchase up to 477,272 shares of common stock, 477,272 Series F-2 Warrants to purchase up to 477,272 shares of common stock and 477,272 Series F-3 Warrants to purchase up to 477,272 shares of common stock, or any combination thereof, as determined by the Underwriter, at the public offering price, less underwriting discounts and commissions, in each case solely to cover over-allotments, if any. The Underwriter partially exercised this option on July 26, 2024, for (i) 336,832 shares of common stock, (ii) 336,832 Series F-1 Warrants to purchase up to 336,832 shares of common stock, (iii) 336,832 Series F-2 Warrants to purchase up to 336,832 shares of common stock and (iv) 336,832 Series F-3 Warrants to purchase up to 336,832 shares of common stock. The 2024 Public Offering closed on July 29, 2024, and the Company received gross proceeds of $3.9 million, without taking into account any underwriting discounts and commissions. A portion of the proceeds were used towards repaying the Secured Convertible Notes, which were repaid in full during the third quarter of 2024. 2024 Warrant Reprice Transaction In June 2024, 2024 Warrant Reprice Transaction Existing Warrants The Company also issued participants in the 2024 Warrant Reprice Transaction a new June 2024 Warrant to purchase a number of shares of common stock equal to 100% of the shares of common stock exercised. The June 2024 Warrants are substantially similar to the Existing Warrants, except that the June 2024 Warrants will (i) be initially exercisable on the six-month anniversary of the date of issuance; (ii) have an exercise price of $2.57; and (iii) have a term of five ( 5 The Company incurred total issuance costs of $96 thousand in conjunction with the 2024 2024 Subsidiary Guarantee Termination On March 24, 2024, in connection with completing certain required conditions to close the DERMAdoctor Divestiture, the Company and the holders of the Secured Convertible Notes entered into a First Amendment (the “ First Amendment Security Agreement Subsidiary Guarantee Consent Subsidiary Guarantee 2024 Subsidiary Guarantee Termination The Company issued, based on the secured parties’ elections, (i) a March 2024 Warrant to a secured party that is exercisable for an aggregate of 1,000,000 shares of common stock (28,572 shares post-Reverse Stock Split) and (ii) Unsecured Convertible Notes to four secured parties that have an aggregate principal amount of $525 thousand or will be convertible into an aggregate of 3,750,000 shares of common stock (107,146 shares post-Reverse Stock Split). The Company incurred total issuance costs of $130 thousand in conjunction with the 2024 Subsidiary Guarantee Termination. The Company allocated $19 thousand of the issuance costs to the Unsecured Convertible Notes which was recorded as a discount in the Company’s condensed consolidated balance sheets. The remaining $111 thousand was allocated to the embedded derivative liability and warrant liability and expensed as “Other expense, net” in the Company’s unaudited condensed consolidated statements of operations, during the nine months ended September 30, 2024. 2023 Warrant Reprice Transaction In December 2023, 2023 Warrant Reprice Transaction The 2023 Warrant Reprice Transaction resulted in gross proceeds of approximately $0.6 million. The Company allocated the gross proceeds between the common stock and December 2023 The Company incurred total issuance costs of $0.2 million in conjunction with the 2023 2023 Private Placement In May 2023, the Company closed a private placement (the “ 2023 Private Placement The Company received gross proceeds of $3.0 million from the 2023 Private Placement. The Company allocated the proceeds from the 2023 Private Placement between the May 2023 Warrants, an embedded derivative liability, and the Secured Convertible Notes by applying the residual fair value methodology. The Company first allocated $1.6 million to the May 2023 Warrants and $0.2 million to the embedded derivative liability with the residual $1.2 million allocated to the Secured Convertible Notes. The embedded derivative liability was subsequently reclassified to equity upon stockholder approval. The Company incurred total issuance costs of $0.7 million in conjunction with the 2023 Private Placement, including a $0.4 million non-cash loss on the warrant modification. The Company allocated $0.3 million of the issuance costs to the Secured Convertible Notes which was recorded as a discount in the Company’s condensed consolidated balance sheets. The remaining $0.4 million was allocated to the embedded derivative liability and warrant liability and expensed as “Other expense, net” in the Company’s unaudited condensed consolidated statements of operations.

Note 10 - Convertible Notes

Note 10 - Convertible Notes	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 10. CONVERTIBLE NOTES Unsecured Convertible Notes In March 2024, the Company issued $525 thousand aggregate principal amount unsecured convertible notes (the “ Unsecured Convertible Notes The Unsecured Convertible Notes may be converted or redeemed for a conversion price equal to $0.14 per share ($4.90 per share post-Reverse Stock Split) at any time at the election of the holder up to the amount of outstanding principal at the time of conversion subject to certain limitations such as beneficial ownership limitations. Upon issuance and as of September 30, 2024, the Unsecured Convertible Notes were convertible for up to 3,750,000 shares of common stock (107,146 shares post-Reverse Stock Split). Upon issuance in March 2024, the lender’s conversion option under the Unsecured Convertible Notes represented an embedded call option requiring bifurcation as an embedded derivative liability because the common stock underlying the option required stockholder approval before the option could be exercised. The fair value of the embedded derivative was determined to be $159 thousand as of March 31, 2024 in accordance with a Black Scholes valuation model. See also Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”. Upon stockholder approval on May 28, 2024, the embedded call option no longer required liability treatment and was reclassified to equity. The fair value of the embedded derivative liability was determined to be $242 thousand as of May 28, 2024. The change of $83 thousand in fair value between March 31, 2024 and May 28, 2024 was recorded as a non-cash loss on change in fair value of embedded derivative liability in the unaudited condensed consolidated statements of operations. See also Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”. The discount to the note recorded for the embedded derivative liability upon issuance and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Unsecured Convertible Notes, assuming that the Unsecured Convertible Notes will be redeemed for cash of $525 thousand at time of maturity as of March 25, 2026. During both the three and nine months ended September 30, 2024, the effective interest rate on the Unsecured Convertible Notes was 144%. During the three and nine months ended September 30, 2024, interest expense recognized, including amortization of the issuance costs and debt discount, was $20 thousand and $35 thousand, respectively, which was included in other expense, net in the unaudited condensed consolidated statements of operations. Secured Convertible Notes In May 2023, the Company issued $3.3 million aggregate principal amount Original Issue Discount Senior Secured Convertible Debentures (the “ Secured Convertible Notes Prior to being paid off, the Secured Convertible Notes could be converted or redeemed for a conversion price equal to $1.30 per share ($45.50 per share post-Reverse Stock Split) at any time at the election of the holder up to the amount of outstanding principal at the time of conversion subject to certain limitations such as beneficial ownership limitations. Upon issuance, the Secured Convertible Notes were convertible for up to 2,538,464 shares of common stock (72,528 shares post-Reverse Stock Split). Beginning June 1, 2023, the Company was required to start making a monthly redemption of 1/18 th The Secured Convertible Notes also provided for a redemption equal to up to 20% of the gross proceeds received by the Company from any financing completed while the Secured Convertible Notes were outstanding. In connection with the 2023 Warrant Reprice Transaction (see Note 12, “Stockholders’ Equity”), the Company made such a payment totaling $126 thousand in cash against the Secured Convertible Notes. In connection with the 2024 Warrant Reprice Transaction (see Note 12, “Stockholders’ Equity”), the Company made such a payment totaling $45 thousand in cash against the Secured Convertible Notes. In connection with the 2024 Public Offering (see Note 12, “Stockholders’ Equity”), the Company repaid the remaining balance of the Secured Convertible Notes with a payment totaling $433 thousand in cash. Upon issuance in May 2023, the lender’s conversion option under the Secured Convertible Notes represented an embedded call option requiring bifurcation as an embedded derivative liability because the common stock underlying the option required stockholder approval before the option could be exercised. The fair value of the embedded derivative was determined to be $209 thousand as of the date of issuance. After stockholder approval of the underlying common stock, the embedded call option no longer required liability treatment and was reclassified to equity. The fair value of the embedded derivative liability was determined to be $169 thousand upon stockholder approval. The change of $40 thousand in fair value between the date of issuance and stockholder approval was recorded as a non-cash gain on change in fair value of embedded derivative liability in the consolidated statements of operations. See also Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”. The lender’s subsequent financing redemption option and certain events of default also represented embedded call options and the Company’s monthly share redemption option represented an embedded put option. The fair value of these options was determined to be immaterial upon issuance and at each subsequent reporting date. The Company allocated $1.2 million of gross proceeds from the 2023 Private Placement to the Secured Convertible Notes. The difference between the $1.2 million allocated to the Secured Convertible Notes and the $3.3 million aggregate principal amount represented discounts for the portion of proceeds allocated to the embedded derivative liability and the May 2023 Warrants (See Note 11, “Common Stock Warrants”) as well as the $0.3 million original issue discount. The Company also allocated $0.3 million of debt issuance costs to the Secured Convertible Notes. The discounts and debt issuance costs were amortized to interest expense using the effective interest rate method over the term of the Secured Convertible Notes. The effective interest rate on the Secured Convertible Notes was 173%. During the three and nine months ended September 30, 2024, interest expense recognized, including amortization of the issuance costs and debt discount, was $12 thousand and $0.8 million, respectively, which was included in other expense, net in the unaudited condensed consolidated statements of operations.

Note 11 - Common Stock Warrants

Note 11 - Common Stock Warrants	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Stockholders' Equity Note, Warrants or Rights Disclosure [Text Block]	NOTE 11. COMMON STOCK WARRANTS See Notes 2, Summary of Significant Accounting Policies ; 3, Fair Value Measurements ; 9, Financing Activities ; and 12, Stockholders Equity for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. July 2024 Pre-Funded Warrants In July 2024, in conjunction with the 2024 Public Offering, the Company issued 2,041,814 pre-funded warrants (in lieu of shares of common stock (see additional discussion in Note 9, “Financing Activities”). The July 2024 Pre-Funded Warrants were classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, were immediately exercisable, did not embody an obligation for us to repurchase our shares, and permitted the holders to receive a fixed number of shares of common stock upon exercise. As of September 30, 2024, all of the July 2024 Pre-Funded Warrants had been exercised, resulting in the Company issuing 2,041,814 shares of common stock. In connection with such exercises, the Company received net proceeds of approximately $20 thousand. July 2024 Warrants In July 2024, in conjunction with the 2024 Public Offering, the Company issued new common stock purchase warrants (collectively the “ July 2024 Warrants ● July 2024 Series F-1 Warrants exercisable for 3,537,212 shares of common stock for an initial exercise price of $1.10 per share through July 30, 2029 (“ July 2024 Series F-1 Warrants ● July 2024 Series F-2 Warrants exercisable for 3,537,212 shares of common stock for an initial exercise price of $1.10 per share through January 29, 2025 (“ July 2024 Series F-2 Warrants ● July 2024 Series F-3 Warrants exercisable for 3,537,212 shares of common stock for an initial exercise price of $1.10 per share through July 29, 2025 (“ July 2024 Series F-3 Warrants The July 2024 Warrants down round feature adjustment was triggered on September 27, 2024, resulting in a reduced exercise price of $0.66. As a result of the reduced exercise price, a deemed dividend of $1.0 million was recognized in accordance with a Black Scholes valuation model. See Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”. June 2024 Warrants In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company issued new common stock purchase warrants (the “ June 2024 Warrants March 2024 Warrant In March 2024, the Company executed the First Amendment and Subsidiary Guarantee Consent as part of the 2024 Subsidiary Guarantee Termination with holders of the Secured Convertible Notes (see Note 10, “Convertible Notes”) in order to close the DERMAdoctor Divestiture (see additional discussion in Note 9, “Financing Activities” and Note 18, “Divestiture and Discontinued Operations”). In exchange for the consent of each holder, the option, at the holder’s election, to receive upon the closing of the DERMAdoctor sale either, a new common stock warrant (the “ March 2024 Warrant The March 2024 Warrant was initially classified as a liability from the date of issuance until Company stockholder approval on May 28, 2024, at which time it was reclassified to equity. December 2023 Warrants In December 2023, in conjunction with the 2023 Warrant Reprice Transaction, the Company issued new common stock purchase warrants (the “ December 2023 Warrants The December 2023 Warrants were initially classified as liabilities from the date of issuance until Company stockholder approval was received on May 28, 2024, at which time it was reclassified to equity. May 2023 Warrants In May 2023, in conjunction with the 2023 Private Placement, the Company issued the following new common stock purchase warrants (collectively, the “ May 2023 Warrants ● May 2023 Series B-1 Warrants exercisable for 2,538,464 shares of common stock (72,528 shares post-Reverse Stock Split) for an initial exercise price of $1.30 per share ($45.50 per share post-Reverse Stock Split) through June 9, 2028 (“ May 2023 B-1 Warrants ● May 2023 Series B-2 Warrants exercisable for 2,538,464 shares of common stock (72,528 shares post-Reverse Stock Split) for an initial exercise price of $1.30 per share ($45.50 per share post-Reverse Stock Split) through June 9, 2025 (“ May 2023 B-2 Warrants In December 2023, in conjunction with the 2023 Warrant Reprice Transaction, the Company amended certain May 2023 Warrants to reduce their exercise prices to $0.25 ($8.75 post-Reverse Stock Split). Immediately after amendment, the following May 2023 Warrants were exercised (while any unexercised May 2023 Warrants maintained an exercise price of $1.30 ($45.50 post-Reverse Stock Split)): ● May 2023 B-1 Warrants exercisable for 634,616 shares of common stock (18,132 shares of post-Reverse Stock Split); and ● May 2023 B-2 Warrants exercisable for 1,894,232 shares of common stock (54,120 shares post-Reverse Stock Split). In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain May 2023 Warrants to reduce their exercise prices to $2.50. Immediately after amendment, the following May 2023 Warrants were exercised (while any unexercised May 2023 Warrants maintained an exercise price of $8.75): ● May 2023 B-1 Warrants exercisable for 54,396 shares of common stock; and ● May 2023 B-2 Warrants exercisable for 18,408 shares of common stock. For the amendments in December 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the May 2023 Warrants of $170 thousand and $47 thousand, respectively. November 2022 Warrants In November 2022, in conjunction with the 2022 Private Placement, the Company issued the following common stock purchase warrants (collectively, the “ November 2022 Warrants ● November 2022 Series A-1 Warrants exercisable for 515,876 shares of common stock (14,741 shares post-Reverse Stock Split) for an initial exercise price of $6.30 per share ($220.50 per share post-Reverse Stock Split) through November 20, 2028 (“ November 2022 A-1 Warrants ● November 2022 Series A-2 Warrants exercisable for 515,876 shares of common stock (14,741 shares post-Reverse Stock Split) for an initial exercise price of $6.30 per share ($220.50 per share post-Reverse Stock Split) through May 20, 2024 (“ November 2022 A-2 Warrants In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain November 2022 Warrants to reduce their exercise prices from $6.30 ($220.50 post-Reverse Stock Split) to $1.50 ($52.50 post-Reverse Stock Split) as follows: ● November 2022 A-1 Warrants exercisable for 436,510 shares of common stock (12,473 shares post-Reverse Stock Split); and ● November 2022 A-2 Warrants exercisable for 436,510 shares of common stock (12,473 shares post-Reverse Stock Split). In May 2024, all November 2022 Series A-2 Warrants for 14,741 shares of common stock remained unexercised and expired. In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain November 2022 Warrants to reduce their exercise prices from $52.50 to $2.50 as follows: ● November 2022 A-1 Warrants exercisable for 12,473 shares of common stock. For the amendments in May 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the November 2022 Warrants of $74 thousand and $16 thousand, respectively. September 2022 Warrants In September 2022, in conjunction with the warrant reprice transaction (the “ 2022 Warrant Reprice Transaction September 2022 Warrants In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain September 2022 Warrants exercisable for 238,574 shares of common stock (6,819 shares post-Reverse Stock Split) to reduce their exercise prices from $6.30 ($220.50 post-Reverse Stock Split) to $1.50 ($52.50 post-Reverse Stock Split). In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain September 2022 Warrants exercisable for 5,104 shares of common stock to reduce their exercise prices from $52.50 to $2.50. For the amendments in May 2023 and June 2024, the Company recognized a loss on modification of common stock warrants related to the September 2022 Warrants of $28 thousand and $6 thousand, respectively. November 2021 Warrants In November 2021, in conjunction with a private placement transaction, the Company issued new common stock purchase warrants (the “ November 2021 Warrants In September 2022, in conjunction with the 2022 Warrant Reprice Transaction, the Company amended all November 2021 Warrants to reduce their exercise prices from $18.55 ($649.25 post-Reverse Stock Split) to $6.30 ($220.50 post-Reverse Stock Split) and extend their termination date to September 11, 2028. Immediately after amendment, November 2021 Warrants were exercised for 7,654 shares of common stock. In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain November 2021 Warrants exercisable for 535,716 shares of common stock (15,308 shares post-Reverse Stock Split) to reduce their exercise prices from $6.30 ($220.50 post-Reverse Stock Split) to $1.50 ($52.50 post-Reverse Stock Split). For the amendments in September 2022 and May 2023, the Company recognized a loss on modification of common stock warrants related to the November 2021 Warrants of $1.5 million and $0.1 million, respectively. July 2020 Warrants In July 2020, in conjunction with a private placement transaction, the Company issued new common stock purchase warrants (the “ July 2020 Warrants ) In September 2022, in conjunction with the 2022 Warrant Reprice Transaction, the Company amended certain July 2020 Warrants exercisable for 137,145 shares of common stock (3,921 shares post-Reverse Stock Split) to reduce their exercise prices from $57.75 ($2,021.25 post-Reverse Stock Split) to $6.30 ($220.50 post-Reverse Stock Split). Immediately after amendment, July 2020 Warrants were exercised for 60,000 shares of common stock (1,715 shares post-Reverse Stock Split). In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain July 2020 Warrants exercisable for 77,145 shares of common stock (2,206 shares post-Reverse Stock Split) to reduce their exercise prices from $6.30 ($220.50 post-Reverse Stock Split) to $1.50 ($52.50 post-Reverse Stock Split). For the amendments in September 2022 and May 2023, the Company recognized a loss on modification of common stock warrants related to the July 2020 Warrants of $0.4 million and $9 thousand, respectively. Summary of Common Stock Warrant Activity and Outstanding Activity related to common stock warrants outstanding at September 30, 2024 and 2023 were as follows: Warrants Weighted- Average Exercise Price Outstanding at December 31, 2022 65,886 $ 269.54 Warrants granted 145,056 $ 45.50 Warrants exercised — $ — Warrants expired — $ — Outstanding at September 30, 2023 210,942 $ 76.23 Outstanding at December 31, 2023 210,946 $ 50.96 Warrants granted 10,730,589 $ 0.69 Pre-funded Warrants granted 2,041,814 $ 0.01 Warrants exercised (90,381 ) $ 2.50 Pre-funded Warrants exercised (2,041,814 ) $ 0.01 Warrants expired (14,879 ) $ 88.87 Outstanding at September 30, 2024 10,836,275 $ 1.41 Common stock warrants outstanding as of September 30, 2024 were as follows: Series Exercise Price* Expiration Date Warrants* July 2020 Warrants $ 2,021.25 January 22, 2026 1,714 July 2020 Warrants $ 52.50 January 22, 2026 2,206 TLF Warrants $ 822.96 January 15, 2026 13 November 2021 Warrants $ 220.50 September 11, 2028 7,654 November 2021 Warrants $ 52.50 September 11, 2028 15,308 September 2022 Warrants $ 220.50 September 11, 2028 2,552 September 2022 Warrants $ 52.50 September 11, 2028 1,715 November 2022 A-1 Warrants $ 220.50 November 20, 2028 2,268 December 2023 Warrants $ 8.75 June 21, 2029 72,256 March 2024 Warrant $ 4.90 March 24, 2029 28,572 June 2024 Warrants $ 2.57 December 17, 2029 90,381 July 2024 F-1 Warrants $ 0.66 July 30, 2029 3,537,212 July 2024 F-2 Warrants $ 0.66 January 29, 2025 3,537,212 July 2024 F-3 Warrants $ 0.66 July 29, 2025 3,537,212 Outstanding at September 30, 2024 10,836,275 * After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024. Summary of Common Stock Warrant Liabilities The following is a reconciliation of the beginning and ending balances for warrant liabilities measured at fair value on a recurring basis (in thousands). See additional information per Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions.” Warrant liabilities as of December 31, 2023 $ 334 Decrease in fair value of December 2023 Warrant liability during period (122 ) Fair value of March 2024 Warrant upon issuance 92 Increase in fair value of March 2024 Warrant liability during period 8 Reclassification of December 2023 Warrant liability to equity during period (212 ) Reclassification of March 2024 Warrant liability to equity during period (100 ) Warrant liabilities as of September 30, 2024 $ —

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Equity [Text Block]	NOTE 12. STOCKHOLDERS EQUITY Authorized Share Capital Under the Company’s Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue up to 150,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with rights and preferences as may be approved by the Company’s Board. Reverse Stock Split Effective May 30, 2024, the Company amended its Certificate of Incorporation to effect a 1-for-35 reverse split of its outstanding common stock. The Reverse Stock Split was approved by the Company’s stockholders on May 28, 2024. As a result of the Reverse Stock Split, every 35 shares of the Company’s pre-reverse split outstanding common stock were combined and reclassified into 1 share of common stock. Proportionate voting rights and other rights of common stockholders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole share. All stock options outstanding, common stock reserved for issuance under the Company’s equity incentive plans, common stock reserved for issuance under the Series B Preferred Stock and outstanding warrants were adjusted by dividing the number of affected shares of common stock by 35 and, as applicable, multiplying the exercise/conversion price by 35. Except as otherwise specifically noted, all share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis, to reflect this 1-for-35 reverse stock split. Preferred Stock There were two series of preferred stock of the Company outstanding during the three and nine months ended September 30, 2024 and 2023 – the Series B Non-Voting Convertible Preferred Stock (“ Series B Preferred Stock Series C Preferred Stock Preferred Stock Ratchet Series B Preferred Stock The Company issued 15,000 shares of Series B Preferred Stock in November 2021 in connection with a private placement transaction. As of September 30, 2024 and 2023, 131 and 6,150 shares of Series B Preferred Stock remained outstanding, respectively. As of September 30, 2024 and 2023, outstanding shares of Series B Preferred Stock were convertible into 527,275 shares of common stock (15,065 shares post-Reverse Stock Split) and 4,735,500 shares of common stock (135,300 shares post-Reverse Stock Split) at a conversion price of $0.25 ($8.75 post-Reverse Stock Split) and $1.30 ($45.50 post-Reverse Stock Split), respectively. In accordance with the Ratchet, the Series B Preferred Stock conversion price was reduced as follows (see also Notes 2, “Summary of Significant Accounting Policies” and 3, “Fair Value Measurements”): ● In September 2022, from $14.00 ($490.00 post-Reverse Stock Split) to $6.30 ($220.50 post-Reverse Stock Split), as a result of the 2022 Warrant Reprice Transaction, resulting in a $5.7 million deemed dividend. ● In April 2023, from $6.30 ($220.50 post-Reverse Stock Split) to $1.30 ($45.50 post-Reverse Stock Split), as a result of the 2023 Private Placement, resulting in a $1.8 million deemed dividend. ● In December 2023, from $1.30 ($45.50 post-Reverse Stock Split) to $0.25 ($8.75 post-Reverse Stock Split), as a result of the 2023 Warrant Reprice Transaction, resulting in a $4.5 million deemed dividend. On January 29, 2024, the Ratchet of the Series B Preferred Stock expired with no further impact because greater than 75% of the originally issued 15,000 Series B Preferred Stock had been converted into common stock. The Series B Preferred Stock conversion price will remain at $0.25 ($8.75 post-Reverse Stock Split) until all remaining Series B Preferred Stock has been converted. Series C Preferred Stock The Company issued 3,250 shares of Series C Preferred Stock in November 2022 in connection with the 2022 Private Placement (see Note 9, “Financing Activities”). As of September 30, 2024 and 2023, zero In accordance with the Ratchet, the Series C Preferred Stock conversion price was reduced as follows (see also Notes 2, “Summary of Significant Accounting Policies” and 3, “Fair Value Measurements”): ● In April 2023, from $6.30 ($220.50 post-Reverse Stock Split) to $1.30 ($45.50 post-Reverse Stock Split), as a result of the 2023 Private Placement, resulting in a $194 thousand deemed dividend. ● In December 2023, from $1.30 ($45.50 post-Reverse Stock Split) to $0.25 ($8.75 post-Reverse Stock Split), as a result of the 2023 Warrant Reprice Transaction, resulting in a $0.5 million deemed dividend. ● In March 2024, from $0.25 ($8.75 post-Reverse Stock Split) to $0.14 ($4.90 post-Reverse Stock Split), as a result of the 2024 First Amendment and the Subsidiary Guarantee Consent, resulting in a $0.4 million deemed dividend. On March 27, 2024, the Ratchet of the Series C Preferred Stock expired with no further impact because greater than 75% of the originally issued 3,250 Series C Preferred Stock had been converted into common stock. Common Stock See Note 9, “Financing Activities” and Note 11, “Common Stock Warrants” for a description of common stock and common stock warrant-related transactions during the three and nine months ended September 30, 2024 and 2023.

Note 13 - Equity-based Compensa

Note 13 - Equity-based Compensation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE 13. EQUITY-BASED COMPENSATION Equity Compensation Plans In October 2007, the Company adopted the 2007 Omnibus Incentive Plan (the “ 2007 Plan ten In March 2017, the Company adopted the 2017 Omnibus Incentive Plan (the “ 2017 Plan NQSOs ISOs SARs Under the terms of the 2017 Plan, the exercise price of NQSOs, ISOs and SARs may not be less than 100% of the fair market value of the common stock on the date of grant and, if ISOs are granted to an owner of more than 10% of the Company’s stock, then not less than 110% of the fair market value of the common stock on the date of grant. The term of awards will not be longer than ten five four Summary of Outstanding Equity Awards The following table summarizes information about the Company’s stock options and restricted stock outstanding at December 31, 2023, and activity during the nine months ended September 30, 2024: (in thousands, except years and per share data) Awards* Weighted- Average Exercise Price* Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2023 4 $ 1,145.87 7.3 $ 1 Restricted stock units granted 5 $ — Options forfeited/cancelled (2 ) $ 535.07 Outstanding at September 30, 2024 7 $ 470.76 8.5 $ 4 Vested and expected to vest at September 30, 2024 7 $ 474.75 8.5 $ 4 Vested and exercisable at September 30, 2024 1 $ 2,122.83 4.7 $ — * After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of September 30, 2024 for options that have an exercise price that is lower than the market price. There were no As of September 30, 2024, total unrecognized compensation cost related to unvested stock options and restricted stock units was approximately $0.1 million. This amount is expected to be recognized as stock-based compensation expense in the Company’s unaudited condensed consolidated statements of operations over the remaining weighted average vesting period of 1.3 years. Equity Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, “Summary of Significant Accounting Policies,” for a description of the accounting policies that the Company applied to value its stock-based awards. During the nine months ended September 30, 2024 and 2023, the Company granted options to employees and directors to purchase an aggregate of zero The weighted-average assumptions used in determining the value of options were as follows: Assumption For the Nine Months Ended September 30, 2023 Expected price volatility 152.99 % Expected term (in years) 6.81 Risk-free interest rate 3.47 % Dividend yield 0.00 % Weighted-average fair value of options granted during the period $ 58.57 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. During the nine months ended September 30, 2024, the Company granted 5,148 shares of restricted stock to employees and directors. During the nine months ended September 30, 2023, the Company granted 5,148 shares of restricted stock (150 shares post-Reverse Stock Split) to employees and directors. For the three months ended September 30, 2024 and 2023, the Company recognized stock-based compensation expense of $22 thousand and $59 thousand, respectively, for option awards to employees and directors. For the nine months ended September 30, 2024 and 2023, the Company recognized stock-based compensation expense of $124 thousand and $194 thousand, respectively, for option awards to employees and directors. Stock-Based Awards to Non-Employees During the three and nine months ended September 30, 2024, the Company did not The Company did not For the three and nine months ended September 30, 2024 the Company recognized stock-based compensation expense of zero Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 3 $ 5 $ 12 $ 16 Sales and marketing 8 18 48 49 General and administrative 11 39 77 136 Total stock-based compensation expense $ 22 $ 62 $ 137 $ 201

Note 14 - Distribution Agreemen

Note 14 - Distribution Agreements	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
License, Collaboration, and Distribution Agreements [Text Block]	NOTE 14. DISTRIBUTION AGREEMENTS Transactions under the Company’s major distribution agreements are recognized upon transfer of control of products sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. Product Sales Discounts and Allowances The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the nine months ended September 30, 2024 (in thousands): Chargebacks, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2023 $ 913 $ 12 $ 21 $ 946 Less discontinued operations (218 ) — — (218 ) Continuing operations balance at December 31, 2023 695 12 21 728 Provision related to sales made in: Current period 39 36 77 152 Payments and customer credits issued (14 ) (36 ) (79 ) (129 ) Balance at September 30, 2024 $ 720 $ 12 $ 19 $ 751 Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. The Company has also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three months ended September 30, 2024 and 2023, the Company earned $153 thousand and $232 thousand, respectively, in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements. During the nine months ended September 30, 2024 and 2023, the Company earned $385 thousand and $519 thousand, respectively, in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements. Under these product distribution arrangements, the Company had a contract liability balance of $0.8 million and $0.7 million as of September 30, 2024 and December 31, 2023, respectively. The contract liability is included in accrued liabilities in the condensed consolidated balance sheets. Over-the-Counter Sales of Avenova Spray Avenova Spray is offered for sale direct to U.S. customers primarily on Amazon.com, the Company’s website (Avenova.com) and Walmart.com. During the three months ended September 30, 2024 and 2023, the revenue generated from Avenova Spray in these channels was $1.8 million and $1.6 million, respectively. During the nine months ended September 30, 2024 and 2023, the revenue generated from Avenova Spray in these channels was $5.4 million and $4.5 million, respectively.

Note 15 - Employee Benefit Plan

Note 15 - Employee Benefit Plan	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 15. EMPLOYEE BENEFIT PLAN The Company has a 401(k) plan covering all eligible employees. The Company provides matching contributions equal to 100% of the first 3% of compensation deferred, plus 50% of the next 2% of compensation deferred. The Company contributed $24 thousand to the 401(k) plan from continuing operations in each of the three months ended September 30, 2024 and 2023. The Company contributed $73 thousand and $70 thousand to the 401(k) plan from continuing operations in the nine months ended September 30, 2024 and 2023, respectively. The Company contributed $8 thousand and $25 thousand to the 401(k) plan from discontinued operations in the three and nine months ended September 30, 2023, respectively.

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 16. RELATED PARTY TRANSACTIONS The following table summarizes information about the Company’s related party revenue and cost of goods sold (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Chongqing Pioneer Pharma Holdings Limited: Revenue $ — $ — $ — $ 1,043 Cost of goods sold — 28 — 923

Note 17 - Segment Reporting

Note 17 - Segment Reporting	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 17. SEGMENT REPORTING The Company operates as one CODM Change in Reportable Segments The Company previously operated in principally two We now manage and report our operating results through one

Note 18 - Divestiture and Disco

Note 18 - Divestiture and Discontinued Operations	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	NOTE 18. DIVESTITURE AND DISCONTINUED OPERATIONS On March 12, 2024, the Company entered into an agreement to sell 100% of the membership units of DERMAdoctor for a closing purchase price of $1.1 million. The sale of the membership units closed, and the DERMAdoctor Divestiture occurred, on March 25, 2024. In order to close the sale, the Company was required to obtain the consent of the holders of the Secured Convertibles Notes (see Note 10, “Convertible Notes”) issued in May 2023 to (i) amend the Security Agreement to remove the Membership Units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement and (ii) terminate the Subsidiary Guarantee, which DERMAdoctor entered into in connection with the issuance of the Secured Convertible Notes. On March 24, 2024, the Company and the secured parties entered into a First Amendment to the Security Agreement, to effect an amendment to the Security Agreement and a Consent and Release to terminate the Subsidiary Guarantee. To obtain the secured parties’ consent and as consideration for the secured parties taking the necessary actions to execute and deliver the First Amendment and the Subsidiary Guarantee Consent, the Company provided each secured party the option, at the secured party’s election, to receive only upon the closing of the DERMAdoctor Sale Transaction either: a March 2024 Warrant or the Unsecured Convertible Notes (see Note 10 “Convertible Notes”). The accounting requirements for reporting the DERMAdoctor business as discontinued operations were met during the first quarter of 2024. Accordingly, the condensed consolidated financial statements and notes to the condensed consolidated financial statements reflect the results of the DERMAdoctor business as a discontinued operation for the periods presented. In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets. The assets and liabilities have been reflected as discontinued operations in the condensed consolidated balance sheets as of December 31, 2023, and consist of the following (in thousands): Balance at December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 206 Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023) 79 Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023) 2,313 Prepaid expenses and other current assets 132 Total current assets, discontinued operations 2,730 Other assets 19 Total assets, discontinued operations $ 2,749 LIABILITIES Liabilities: Current liabilities: Accounts payable $ 224 Accrued liabilities 347 Operating lease liabilities 127 Total current liabilities, discontinued operations 698 Total liabilities, discontinued operations $ 698 In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the unaudited condensed consolidated statements of operations. The results of DERMAdoctor’s operations for the nine months ended September 30, 2024 and 2023 have been reflected as discontinued operations in the unaudited condensed consolidated statements of operations and consist of the following (in thousands): Nine Months Ended 2024 2023 Sales: Product revenue, net $ 717 $ 2,645 Total sales, net 717 2,645 Cost of goods sold 493 1,566 Gross profit 224 1,079 Operating expenses Research and development 2 28 Sales and marketing 292 1,413 General and administrative 48 749 Total operating expenses 342 2,190 Operating loss (118 ) (1,111 ) Other expense, net (6 ) 5 Net loss from discontinued operations $ (124 ) $ (1,106 ) In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the unaudited condensed consolidated statements of cash flows. The results of DERMAdoctor for the nine months ended September 30, 2024 and 2023 have been reflected as discontinued operations in the unaudited condensed consolidated statements of cash flows and consist of the following (in thousands): Nine Months Ended September 30, 2024 2023 Operating activities: Net loss from discontinued operations $ (124 ) $ (1,106 ) Adjustments to reconcile net loss to net cash used in operating activities: Amortization of intangible assets — 114 Non-cash right-of-use amortization — 83 Changes in operating assets and liabilities: Accounts receivable (262 ) 144 Inventory 183 139 Prepaid expenses and other current assets (4 ) 146 Other assets 15 (8 ) Accounts payable and accrued liabilities 63 299 Operating lease liabilities (31 ) (89 ) Net cash used in operating activities, discontinued operations (160 ) (278 ) Investing activities: Cash transferred to New Age Investments, LLC (46 ) — Purchases of property and equipment — (1 ) Net cash used in investing activities, discontinued operations (46 ) (1 ) Net decrease in cash and cash equivalents, discontinued operations $ (206 ) $ (279 )

Note 19 - Subsequent Events

Note 19 - Subsequent Events	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 19. SUBSEQUENT EVENTS The Company has evaluated all subsequent events through the filing date of this Form 10-Q , Asset Sale Transaction--Amendment to Asset Purchase Agreement and Bridge Loan On November 5, 2024, the Company and PRN entered into the APA Amendment to the Original Purchase Agreement. The Purchase Agreement, consistent with the Original Purchase Agreement, continues to provide for the sale of the Avenova Assets to PRN, subject to meeting certain closing conditions including receiving stockholder approval of the Asset Sale Transaction. The APA Amendment provides for the Revised PRN Transaction Terms, including the following primary revisions to the Original Purchase Agreement: (i) an increase in the base purchase price to $11.5 million from $9.5 million; (ii) the removal of debt financing contingencies and related PRN representations, while adding a new PRN representation that it has sufficient funding for the $11.5 million purchase price; (iii) PRN providing the Company with the Bridge Loan; and (iv) PRN providing the Company with the Equity Commitment Letter. On November 5, 2024, the Company also entered into the Bridge Loan that provides for the Company receiving a secured loan of up to $1.0 million from PRN as lender that will be funded in two tranches of $0.5 million each upon the Company providing written notice to PRN on or after November 22, 2024 and on or after December 6, 2024. The amounts borrowed under the Bridge Loan are required to be used for working capital purposes, will bear interest at a rate of 10% per annum and be secured by all of the Company’s assets as collateral. The Bridge Loan is a short term secured loan that is to be repaid upon the earlier of the closing of the Asset Sale Transaction (to be repaid from the purchase price), immediately upon termination of the Purchase Agreement or February 28, 2025. If any Event of Default (as defined in the Bridge Loan) occurs, the outstanding principal amount of the Bridge Loan, plus any accrued and unpaid interest, shall become immediately due and payable with the interest rate on the outstanding principal amount of the Bridge Loan increasing to 12% per annum. For more information regarding the Asset Sale Transaction (including the Revised PRN Transaction Terms, the APA Amendment and the Bridge Loan) and the Dissolution, please see the Company’s Current Reports on Form 8-K filed with the SEC on September 20, 2024, October 29, 2024 and November 6, 2024 and the Special Meeting Proxy Statement and related supplements.

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	ITEM 5. OTHER INFORMATION Rule 10b5-1 Trading Arrangements During the nine months ended September 30, 2024, none
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and are expressed in U.S. dollars. In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position and operating results.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its former wholly-owned subsidiary, DERMAdoctor, as of and for the nine months ended September 30, 2024. All significant intercompany balances and transactions have been eliminated in consolidation. As of March 25, 2024, the Company divested its wholly-owned subsidiary pursuant to the DERMAdoctor Divestiture. The financial results for DERMAdoctor have been presented as discontinued operations in the accompanying condensed consolidated financial statements. For the nine months ended September 30, 2024, all gains and losses on disposition, along with the sales, costs and expenses attributable to discontinued operations, have been aggregated in the captions entitled “Loss on divestiture of subsidiary” and “Net loss from discontinued operations” in our unaudited condensed consolidated statements of operations.
Reclassification, Comparability Adjustment [Policy Text Block]	Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these unaudited condensed consolidated financial statements to conform to current period classifications. The prior year amounts have been modified in these unaudited condensed consolidated financial statements to properly report amounts under current operations and discontinued operations (see Note 18, “Divestiture and Discontinued Operations”). Further, certain prior period operating lease balances on the Condensed Consolidated Statements of Cash Flows originally reported within changes in “Operating lease right-of-use assets” are now within “Non-cash right-of-use amortization” to conform to the current year presentation. These changes had no impact on the Company's net decrease in case, cash equivalents, and restricted cash in the prior year nor any of the subtotal changes of cash from operating, investing, or financing activities.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, contract liabilities related to product sales such as product returns, assumptions for valuing warrants, assumptions for valuing derivative liabilities, the fair value of contingent consideration, intangible assets, goodwill, stock-based compensation, income taxes and other contingencies. These estimates are based on management’s best estimates and judgment. Actual results may differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on management’s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.
Unaudited Interim Financial Information, Policy [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Information The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation. The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The unaudited condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 26, 2024 and amended on March 29, 2024 (collectively, the “ 2023 Annual Report
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of September 30, 2024 and December 31, 2023, the Company’s cash and cash equivalents were held in a major financial institution in the United States. The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands): September 30, December 31, 2024 2023 Cash and cash equivalents $ 776 $ 3,130 Cash and cash equivalents, discontinued operations — (206 ) Restricted cash included in other assets 477 476 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 1,253 $ 3,400 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. The Company has a significant amount of its cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. During the three and nine months ended September 30, 2024 and 2023, revenues from significant product categories were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Avenova Spray $ 2,170 $ 2,064 $ 6,391 $ 5,759 NeutroPhase — — — 1,043 Other products 254 407 1,044 1,524 Total product revenue, net 2,424 2,471 7,435 8,326 Other revenue, net 17 10 37 28 Total sales, net $ 2,441 $ 2,481 $ 7,472 $ 8,354 During the three and nine months ended September 30, 2024 and 2023, revenues were derived primarily from sales of Avenova branded products, directly to consumers through Amazon.com and Avenova.com. Sales of Avenova Spray via Amazon comprised 73% and 66% of total Avenova Spray net revenue during the three months ended September 30, 2024 and 2023, respectively. Sales of Avenova Spray via Amazon comprised 74% and 68% of total Avenova Spray net revenue during the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and December 31, 2023, accounts receivable from continuing operations from our major distribution partners and major retailers greater than 10% were as follows: September 30, December 31, Major distribution partner 2024 2023 Major U.S. Retailer A 43 % 22 % Avenova Spray Pharmacy Distributor A 31 % 14 % Chongqing Pioneer Pharma Holdings Limited * % 36 % * Less than 10% The Company relies on one
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ ASC Fair Value Measurements and Disclosures Level 1 – quoted prices in active markets for identical assets or liabilities; Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. See additional information in Note 3, “Fair Value Measurements”.
Credit Loss, Financial Instrument [Policy Text Block]	Allowance for Credit Losses The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company’s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand as of September 30, 2024 and December 31, 2023.
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. The Company utilizes a contract manufacturer to produce its products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At September 30, 2024 and December 31, 2023, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $126 thousand and $264 thousand, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Business Combinations, Goodwill and Indefinite-Lived Intangible Assets We account for Business Combinations Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Goodwill is evaluated for impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary. If it is determined, based on qualitative factors, that the fair value of the reporting unit may more likely than not be less than carrying amount, or if significant adverse changes in the Company’s future financial performance occur that could materially impact fair value, a quantitative goodwill impairment test would be required. Additionally, management can elect to forgo the qualitative assessment and perform the quantitative test. If the qualitative assessment indicates that the quantitative analysis should be performed, or if management elects to bypass a qualitative assessment, the Company then evaluates goodwill for impairment by comparing the fair value of the reporting unit to its carrying amount, including goodwill. The quantitative assessment for goodwill requires management to estimate the fair value of the Company’s reporting units using either an income or market approach or a combination thereof. Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Company’s cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. The Company did not
Valuation of Contingent Consideration from Business Combination Policy [Policy Text Block]	Valuation of Contingent Consideration Resulting from a Business Combination In connection with the DERMAdoctor acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the condensed consolidated statements of operations. The DERMAdoctor acquisition milestone events consisted of financial targets for calendar years 2022 and 2023 which were not met. As a result, the liability recorded for potential earn out payments in the Company’s condensed consolidated balance sheets was zero
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets The Company’s intangible assets that do not have indefinite lives, primarily trade secrets and product formulations, are amortized over their estimated useful lives. All of the Company’s intangible assets subject to amortization and other long-lived assets, are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment The Company did not
Lessee, Leases [Policy Text Block]	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received. The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not applied. Leases include variable components (e.g., common area maintenance) that are paid separately from the monthly base payment based on actual costs incurred and therefore were not included in the right-of-use assets and lease liability but are reflected as an expense in the period incurred. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheets as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
Warrant Liabilities [Policy Text Block]	Common Stock Warrants The Company accounts for the issuance of common stock purchase warrants issued in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, the Company also classifies as liabilities any warrants during the period which the shares underlying the contract are subject to stockholder approval before the warrant can be exercised. For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions” and Note 11, “Common Stock Warrants”, subheading “Summary of Common Stock Warrant Liabilities”. Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black Scholes option pricing model. See Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”.
Preferred Stock [Policy Text Block]	Preferred Stock Terms of the Company’s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 12, “Stockholders’ Equity”). The applicable Ratchet provisions of the Company’s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. When a conversion price was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend was measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the anti-dilution protection feature). These fair values were determined using the Black Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See also Note 3, “Fair Value Measurements”, subheading “Black Scholes Valuation Models and Assumptions”.
Revenue [Policy Text Block]	Revenue Recognition The Company’s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is recognized in accordance with the amount of consideration which the Company expects to receive. Revenue generated from end consumers through third-party online retailers, such as Amazon, as well as the Company’s web store (Avenova.com) is recognized on a “sell-through” basis when control of the goods is transferred to the consumer, which generally occurs upon delivery of the products to the party fulfilling the consumer’s order. Revenue is recorded net of any discounts and estimates for refunds and product returns. Fees paid to third-party online retailers and fulfillment parties are recorded as incurred in the Company’s condensed consolidated statements of operations. Fulfillment and shipping and handling fees are recorded as product cost of goods sold. Selling commissions and advertising and promotion fees are recorded as sales and marketing expenses. Revenue generated through major pharmacy distributors is recognized on a “sell-in” basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for products sold is typically due 60 days after delivery to the distributor. Revenue generated from end consumers through the Company’s partner pharmacies is recognized on a “sell-through” basis when control of the goods is transferred to the consumer. Revenue generated from other retailers is recognized on a “sell-through” basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third-party carrier who is delivering the products to the retailer. The Company defers recognition for pre-payments until the Company’s performance obligations are satisfied.
Cost of Goods and Service [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, third-party fulfillment fees, and other costs associated with products sold. Cost of goods sold also includes any necessary allowances for excess and obsolete inventory as well as lower of cost and estimated net realizable value.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities.
Patent Costs Policy [Policy Text Block]	Patent Costs Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations.
Advertising Cost [Policy Text Block]	Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $0.1 million and $0.3 million for the three months ended September 30, 2024 and 2023, respectively. Advertising expenses were $0.5 million and $0.8 million for the nine months ended September 30, 2024 and 2023, respectively.
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“ RSUs
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“ EPS Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. For the three and nine months ended September 30, 2024 and 2023, the Series B Preferred Stock and Series C Preferred Stock (both as defined below) were excluded from the computation of diluted net loss per share as their inclusion on an “if converted” basis would have been anti-dilutive. The Series B Preferred Stock and Series C Preferred Stock were considered anti-dilutive because such securities did not have a contractual obligation to participate in losses of the Company. The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Balance at September 30, 2024* 2023* Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “ Series B Preferred Stock 15,065 135,300 Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “ Series C Preferred Stock — 24,134 Stock options 6,893 4,240 Stock warrants 10,836,275 210,929 10,858,233 374,603 * After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, “Summary of Significant Accounting Policies” included in our 2023 Annual Report. The Company continues to evaluate the potential impact of adopting the new accounting guidance on its consolidated financial position, results of operations and cash flows.

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	September 30, December 31, 2024 2023 Cash and cash equivalents $ 776 $ 3,130 Cash and cash equivalents, discontinued operations — (206 ) Restricted cash included in other assets 477 476 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 1,253 $ 3,400
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Avenova Spray $ 2,170 $ 2,064 $ 6,391 $ 5,759 NeutroPhase — — — 1,043 Other products 254 407 1,044 1,524 Total product revenue, net 2,424 2,471 7,435 8,326 Other revenue, net 17 10 37 28 Total sales, net $ 2,441 $ 2,481 $ 7,472 $ 8,354
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	September 30, December 31, Major distribution partner 2024 2023 Major U.S. Retailer A 43 % 22 % Avenova Spray Pharmacy Distributor A 31 % 14 % Chongqing Pioneer Pharma Holdings Limited * % 36 %
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Balance at September 30, 2024* 2023* Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “ Series B Preferred Stock 15,065 135,300 Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “ Series C Preferred Stock — 24,134 Stock options 6,893 4,240 Stock warrants 10,836,275 210,929 10,858,233 374,603

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable September Items Inputs Inputs 30, 2024 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 477 $ 477 $ — $ — Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable December Items Inputs Inputs 31, 2023 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 476 $ 476 $ — $ — Liabilities Warrant liabilities $ 334 $ — $ 334 $ —
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	May 2023 Warrants May 2023 Warrants December 2023 Warrants December 2023 Warrants Measurement event Issuance Stockholder Approval Reporting Date Stockholder Approval Date May 1, 2023 June 9, 2023 December 31, 2023 May 28, 2024 Total Value $1.6 million $1.4 million $0.3 million $0.2 million Gain (Loss) not applicable $0.2 million $56 thousand $(51 thousand) Assumptions: Exercise price $ 45.50 $ 45.50 $ 8.75 $ 8.75 Market price $ 25.20 (a) $ 23.80 $ 7.14 $ 4.94 Volatility 80.1 % 77.6 % 79.3 % 83.9 % Risk-free rate 3.60 - 4.04 % 3.92 - 4.59 % 3.85 % 4.56 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % Term (years) 2.1 - 5.1 2.0 - 5.0 5.5 5.1 March March 2024 2024 Warrant Warrant Measurement event Reporting Date Stockholder Approval Date March 31, 2024 May 28, 2024 Total Value $0.1 million $0.1 million Gain (Loss) $21 thousand $(28 thousand) Assumptions: Exercise price $ 4.90 $ 4.90 Market price $ 3.66 $ 4.94 Volatility 86.9 % 83.9 % Risk-free rate 4.21 % 4.56 % Dividend yield 0.0 % 0.0 % Term (years) 5.5 5.3 July 2020, November 2021, September 2022 & November 2022 Warrants Measurement event Prior to amendment After amendment Date April 27, 2023 April 27, 2023 Total Value $0.3 million $0.5 million Loss not applicable $0.2 million Assumptions: Exercise price $ 220.50 $ 52.50 Market price $ 25.20 (a) $ 25.20 (a) Volatility 80.1 % 80.1 % Risk-free rate 3.59 - 4.73 % 3.59 - 4.73 % Dividend yield 0.0 % 0.0 % Term (years) 1.1 - 5.6 1.1 - 5.6 May 2023 Warrants Measurement event Prior to amendment After amendment Date December 21, 2023 December 21, 2023 Total Value $56 thousand $0.2 million Loss not applicable $0.1 million Assumptions: Exercise price $ 45.50 $ 8.75 Market price $ 8.07 $ 8.07 Volatility 79.3 % 79.3 % Risk-free rate 3.92 - 4.62 % 3.92 - 4.62 % Dividend yield 0.0 % 0.0 % Term (years) 1.5 - 4.5 1.5 - 4.5 September 2022, November 2022, and May 2023 Warrants Measurement event Prior to amendment After amendment Date June 14, 2024 June 14, 2024 Total Value $66 thousand $0.1 million Loss not applicable $70 thousand Assumptions: Exercise price $ 8.75-52.50 $ 2.50 Market price $ 2.51 $ 2.51 Volatility 89.3 % 89.3 % Risk-free rate 4.27 - 5.08 % 4.27 - 5.08 % Dividend yield 0.0 % 0.0 % Term (years) 1.0 - 4.4 1.0 - 4.4 Series F-1 Measurement event Prior to adjustment After adjustment Date September 27, 2024 September 27, 2024 Total value $1.7 million $1.9 million Deemed dividend not applicable $0.2 million Assumptions: Exercise price $ 1.10 $ 0.66 Market price $ 0.71 $ 0.71 Volatility 97.1 % 97.1 % Risk-free rate 3.55 % 3.55 % Dividend yield 0.0 % 0.0 % Term (in years) 4.84 4.84 Series F-2 Measurement event Prior to adjustment After adjustment Date September 27, 2024 September 27, 2024 Total value $0.2 million $0.6 million Deemed dividend not applicable $0.4 million Assumptions: Exercise price $ 1.10 $ 0.66 Market price $ 0.71 $ 0.71 Volatility 97.1 % 97.1 % Risk-free rate 4.64 % 4.64 % Dividend yield 0.0 % 0.0 % Term (in years) 0.34 0.34 Series F-3 Measurement event Prior to adjustment After adjustment Date September 27, 2024 September 27, 2024 Total value $0.6 million $1.0 million Deemed dividend not applicable $0.4 million Assumptions: Exercise price $ 1.10 $ 0.66 Market price $ 0.71 $ 0.71 Volatility 97.1 % 97.1 % Risk-free rate 4.10 % 4.10 % Dividend yield 0.0 % 0.0 % Term (in years) 0.84 0.84 Series B & C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date April 27, 2023 April 27, 2023 Total value (b) $9.6 million $11.6 million Deemed dividend not applicable $2.0 million Assumptions: Exercise price $ 220.50 $ 45.50 Market price $ 25.20 (a) $ 25.20 (a) Volatility 80.1 % 80.1 % Risk-free rate 4.91 % 4.91 % Dividend yield 0.0 % 0.0 % Term (in years) 0.8 0.8 Series B & C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date December 21, 2023 December 21, 2023 Total value (b) $1.7 million $6.8 million Deemed dividend not applicable $5.1 million Assumptions: Exercise price $ 45.50 $ 8.75 Market price $ 8.07 $ 8.07 Volatility 79.3 % 79.3 % Risk-free rate 5.43 % 5.43 % Dividend yield 0.0 % 0.0 % Term (years) 0.3 0.3 Series C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date March 24, 2024 March 24, 2024 Total value (b) $0.5 million $0.9 million Deemed dividend not applicable $0.4 million Assumptions: Exercise price $ 8.75 $ 4.90 Market price $ 4.77 $ 4.77 Volatility 79.9 % 79.9 % Risk-free rate 5.51 % 5.51 % Dividend yield 0.0 % 0.0 % Term (in years) 0.1 0.1 Unsecured Convertible Notes derivative Unsecured Convertible Notes derivative Measurement event Issuance Shareholder Approval Date March 25, 2024 May 28, 2024 Total value $0.2 million $0.2 million Gain (Loss) not applicable $(82 thousand) Assumptions: Exercise price $ 4.90 $ 4.90 Market price $ 4.51 $ 4.94 Volatility 86.9 % 83.9 % Risk-free rate 4.54 % 4.94 % Dividend yield 0.0 % 0.0 % Term (years) 2.0 1.8 Secured Convertible Notes derivative Secured Convertible Notes derivative Measurement event Issuance Shareholder Approval Date April 27, 2023 June 9, 2023 Total value (b) $0.2 million $0.2 million Gain not applicable $40 thousand Assumptions: Exercise price $ 45.50 $ 45.50 Market price $ 25.20 (a) $ 23.80 Volatility 80.1 % 76.9 % Risk-free rate 4.88 % 5.41 % Dividend yield 0.0 % 0.0 % Term (years) 0.8 0.7

Note 4 - Prepaid Expenses and_2

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	September 30, December 31, 2024 2023 Prepaid insurance $ 73 $ 66 Prepaid dues and subscriptions 63 85 Prepaid taxes 49 83 Prepaid inventory 25 73 Other 116 81 Prepaid expenses from discontinued operations — (132 ) Total prepaid expenses and other current assets $ 326 $ 256

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 2024 2023 Raw materials and supplies $ 144 $ 1,027 Finished goods 455 2,477 Less: Reserve for excess and obsolete inventory (126 ) (627 ) Inventory, net of reserves, from discontinued operations — (2,313 ) Total inventory, net $ 473 $ 564

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, 2024 2023 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 414 431 Leasehold improvements 152 152 Total property and equipment, at cost 743 760 Less: accumulated depreciation (682 ) (673 ) Total property and equipment, net $ 61 $ 87

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2024 2023 Contract liabilities (see Note 14) $ 751 $ 946 Employee payroll and benefits 288 341 Other 108 229 Accrued liabilities from discontinued operations — (347 ) Total accrued liabilities $ 1,147 $ 1,169

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Lease, Cost [Table Text Block]	For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease – expense $ 100 $ 100 $ 300 $ 300 Operating lease from discontinued operations – expense — 30 — 91 Operating lease – included in operating cash flow 117 113 310 301 Operating lease from discontinued operations – included in operating cash flow — 33 — 97 September 30, 2024 September 30, 2023 Weighted-average remaining lease term (in years) 2.8 3.6 Weighted-average discount rate 5 % 5 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	2024 $ 117 2025 439 2026 444 2027 290 Total future minimum lease payments 1,290 Less: Imputed interest (79 ) Total $ 1,211 Reported as: Operating lease liability $ 390 Operating lease liability – non-current 821 Total $ 1,211

Note 11 - Common Stock Warran_2

Note 11 - Common Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Weighted- Average Exercise Price Outstanding at December 31, 2022 65,886 $ 269.54 Warrants granted 145,056 $ 45.50 Warrants exercised — $ — Warrants expired — $ — Outstanding at September 30, 2023 210,942 $ 76.23 Outstanding at December 31, 2023 210,946 $ 50.96 Warrants granted 10,730,589 $ 0.69 Pre-funded Warrants granted 2,041,814 $ 0.01 Warrants exercised (90,381 ) $ 2.50 Pre-funded Warrants exercised (2,041,814 ) $ 0.01 Warrants expired (14,879 ) $ 88.87 Outstanding at September 30, 2024 10,836,275 $ 1.41
Schedule of Stockholders' Equity Note, Warrants or Rights Outstanding, Activity [Table Text Block]	Series Exercise Price* Expiration Date Warrants* July 2020 Warrants $ 2,021.25 January 22, 2026 1,714 July 2020 Warrants $ 52.50 January 22, 2026 2,206 TLF Warrants $ 822.96 January 15, 2026 13 November 2021 Warrants $ 220.50 September 11, 2028 7,654 November 2021 Warrants $ 52.50 September 11, 2028 15,308 September 2022 Warrants $ 220.50 September 11, 2028 2,552 September 2022 Warrants $ 52.50 September 11, 2028 1,715 November 2022 A-1 Warrants $ 220.50 November 20, 2028 2,268 December 2023 Warrants $ 8.75 June 21, 2029 72,256 March 2024 Warrant $ 4.90 March 24, 2029 28,572 June 2024 Warrants $ 2.57 December 17, 2029 90,381 July 2024 F-1 Warrants $ 0.66 July 30, 2029 3,537,212 July 2024 F-2 Warrants $ 0.66 January 29, 2025 3,537,212 July 2024 F-3 Warrants $ 0.66 July 29, 2025 3,537,212 Outstanding at September 30, 2024 10,836,275
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant liabilities as of December 31, 2023 $ 334 Decrease in fair value of December 2023 Warrant liability during period (122 ) Fair value of March 2024 Warrant upon issuance 92 Increase in fair value of March 2024 Warrant liability during period 8 Reclassification of December 2023 Warrant liability to equity during period (212 ) Reclassification of March 2024 Warrant liability to equity during period (100 ) Warrant liabilities as of September 30, 2024 $ —

Note 13 - Equity-based Compen_2

Note 13 - Equity-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	(in thousands, except years and per share data) Awards* Weighted- Average Exercise Price* Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2023 4 $ 1,145.87 7.3 $ 1 Restricted stock units granted 5 $ — Options forfeited/cancelled (2 ) $ 535.07 Outstanding at September 30, 2024 7 $ 470.76 8.5 $ 4 Vested and expected to vest at September 30, 2024 7 $ 474.75 8.5 $ 4 Vested and exercisable at September 30, 2024 1 $ 2,122.83 4.7 $ —
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and development $ 3 $ 5 $ 12 $ 16 Sales and marketing 8 18 48 49 General and administrative 11 39 77 136 Total stock-based compensation expense $ 22 $ 62 $ 137 $ 201
Employees and Directors [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Assumption For the Nine Months Ended September 30, 2023 Expected price volatility 152.99 % Expected term (in years) 6.81 Risk-free interest rate 3.47 % Dividend yield 0.00 % Weighted-average fair value of options granted during the period $ 58.57

Note 14 - Distribution Agreem_2

Note 14 - Distribution Agreements (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Chargebacks, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2023 $ 913 $ 12 $ 21 $ 946 Less discontinued operations (218 ) — — (218 ) Continuing operations balance at December 31, 2023 695 12 21 728 Provision related to sales made in: Current period 39 36 77 152 Payments and customer credits issued (14 ) (36 ) (79 ) (129 ) Balance at September 30, 2024 $ 720 $ 12 $ 19 $ 751

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Chongqing Pioneer Pharma Holdings Limited: Revenue $ — $ — $ — $ 1,043 Cost of goods sold — 28 — 923

Note 18 - Divestiture and Dis_2

Note 18 - Divestiture and Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	Balance at December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 206 Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023) 79 Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023) 2,313 Prepaid expenses and other current assets 132 Total current assets, discontinued operations 2,730 Other assets 19 Total assets, discontinued operations $ 2,749 LIABILITIES Liabilities: Current liabilities: Accounts payable $ 224 Accrued liabilities 347 Operating lease liabilities 127 Total current liabilities, discontinued operations 698 Total liabilities, discontinued operations $ 698 Nine Months Ended 2024 2023 Sales: Product revenue, net $ 717 $ 2,645 Total sales, net 717 2,645 Cost of goods sold 493 1,566 Gross profit 224 1,079 Operating expenses Research and development 2 28 Sales and marketing 292 1,413 General and administrative 48 749 Total operating expenses 342 2,190 Operating loss (118 ) (1,111 ) Other expense, net (6 ) 5 Net loss from discontinued operations $ (124 ) $ (1,106 ) Nine Months Ended September 30, 2024 2023 Operating activities: Net loss from discontinued operations $ (124 ) $ (1,106 ) Adjustments to reconcile net loss to net cash used in operating activities: Amortization of intangible assets — 114 Non-cash right-of-use amortization — 83 Changes in operating assets and liabilities: Accounts receivable (262 ) 144 Inventory 183 139 Prepaid expenses and other current assets (4 ) 146 Other assets 15 (8 ) Accounts payable and accrued liabilities 63 299 Operating lease liabilities (31 ) (89 ) Net cash used in operating activities, discontinued operations (160 ) (278 ) Investing activities: Cash transferred to New Age Investments, LLC (46 ) — Purchases of property and equipment — (1 ) Net cash used in investing activities, discontinued operations (46 ) (1 ) Net decrease in cash and cash equivalents, discontinued operations $ (206 ) $ (279 )

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Nov. 05, 2024 USD ($)

Sep. 19, 2024 USD ($)

Sep. 17, 2024 USD ($)

Sep. 16, 2024 USD ($)

May 30, 2024

[1]

Mar. 25, 2024 USD ($)

Sep. 30, 2024 USD ($)

Mar. 31, 2024 USD ($)

Sep. 30, 2023 USD ($)

Sep. 30, 2024 USD ($)

Sep. 30, 2023 USD ($)

Dec. 31, 2023

Number of Reportable Segments

1

2

Proceeds from Divestiture of Businesses

$ 1,070

$ 0

Gain (Loss) on Disposition of Business

$ 0

$ 0

$ (865)

$ 0

Discontinued Operations, Disposed of by Sale [Member] | DERMAdoctor [Member]

Proceeds from Divestiture of Businesses

$ 1,100

Gain (Loss) on Disposition of Business

$ (900)

Subsequent Event [Member] | Roundtable Healthcare Partners [Member] | Maximum [Member]

Equity Funding Commitment Receivable

$ 13,000

Subsequent Event [Member] | Bridge Loan [Member]

Debt Instrument, Face Amount

$ 1,000

Debt Instrument, Interest Rate, Stated Percentage

10%

Subsequent Event [Member] | Bridge Loan [Member] | Tranche One, Bridge Loan [Member]

Debt Instrument, Funded Amount

$ 500

Subsequent Event [Member] | Bridge Loan [Member] | Tranche Two, Bridge Loan [Member]

Debt Instrument, Funded Amount

500

APA Amendment [Member] | Subsequent Event [Member]

Asset Acquisition, Price of Acquisition, Expected

$ 11,500

Original Purchase Agreement [Member]

Asset Acquisition, Price of Acquisition, Expected

$ 9,500

$ 9,500

$ 9,500

Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

35

35

[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands			3 Months Ended			9 Months Ended
	May 30, 2024	[1]	Sep. 30, 2024 USD ($)	Mar. 31, 2024	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Number of Major Source Manufacturers						1
Accounts Receivable, Allowance for Credit Loss			$ 3			$ 3		$ 3
Inventory Valuation Reserves			126			126		264
Goodwill and Intangible Asset Impairment			0		$ 0	0	$ 0
Business Combination, Contingent Consideration, Liability			0			0		$ 0
Impairment, Long-Lived Asset, Held-for-Use			0		0	0	0
Payment for Product Supply Period				60 days
Advertising Expense			$ 100		$ 300	$ 500	$ 800
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	35		35
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life			5 years			5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			7 years			7 years
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years			3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years			5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life			5 years			5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life			7 years			7 years
Revenue from Contract with Customer Benchmark [Member] | Distributor Concentration Risk [Member] | Avenova Spray [Member]
Concentration Risk, Percentage			73%		66%	74%	68%
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Cash and cash equivalents	$ 776	$ 3,130
Cash and cash equivalents, discontinued operations	0	(206)
Restricted cash included in other assets	477	476
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows	$ 1,253	$ 3,400

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total sales, net	$ 2,441	$ 2,481	$ 7,472	$ 8,354
Avenova Spray [Member]
Total sales, net	2,170	2,064	6,391	5,759
NeutroPhase [Member]
Total sales, net	0	0	0	1,043
Other Products [member]
Total sales, net	254	407	1,044	1,524
Total Product Revenue [Member]
Total sales, net	2,424	2,471	7,435	8,326
Product and Service, Other [Member]
Total sales, net	$ 17	$ 10	$ 37	$ 28

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) - Accounts Receivable [Member] - Customer Concentration Risk [Member]	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Major U.S. Retailer A [Member]
Accounts receivable, concentration risk	43%	22%
Distributor A [Member]
Accounts receivable, concentration risk	31%	14%
Chongqing Pioneer Pharma Holdings Limited [Member]
Accounts receivable, concentration risk		36%

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023
Anti-dilutive securities (in shares)	[1]	10,858,233	374,603
Series B Preferred Stock [Member]
Anti-dilutive securities (in shares)	[1]	15,065	135,300
Series C Preferred Stock [Member]
Anti-dilutive securities (in shares)	[1]	0	24,134
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	[1]	6,893	4,240
Warrant [Member]
Anti-dilutive securities (in shares)	[1]	10,836,275	210,929
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Restricted cash held as a certificate of deposit	$ 477	$ 476
Warrant liabilities		334
Fair Value, Inputs, Level 1 [Member]
Restricted cash held as a certificate of deposit	477	476
Warrant liabilities		0
Fair Value, Inputs, Level 2 [Member]
Restricted cash held as a certificate of deposit	0	0
Warrant liabilities		334
Fair Value, Inputs, Level 3 [Member]
Restricted cash held as a certificate of deposit	$ 0	0
Warrant liabilities		$ 0

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details) $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended
		Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Non-cash gain on changes in fair value of warrant liabilities				$ 0	$ 0	$ (114)	$ (216)
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value	[1]			$ 9,600		$ 9,600
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				220.5		220.5
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member]
Measurement Input	[2]			25.2		25.2
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.801		0.801
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0491		0.0491
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.8		0.8
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value	[1]			$ 1,700		$ 1,700
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				45.5		45.5
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member]
Measurement Input				8.07		8.07
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.793		0.793
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0543		0.0543
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.3		0.3
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member]
Total Value	[1]			$ 500		$ 500
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				8.75		8.75
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Option Volatility [Member]
Measurement Input				0.799		0.799
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0551		0.0551
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.1		0.1
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member]
Total value, embedded				$ 200		$ 200
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative				4.9		4.9
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Share Price [Member]
Measurement input, embedded derivative				4.51		4.51
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative				0.869		0.869
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative				0.0454		0.0454
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative				0		0
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Term [Member]
Measurement input, embedded derivative				2		2
Issuance, April 27, 2023 [Member] | Convertible Debt [Member]
Total value, embedded	[3]			$ 200		$ 200
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative				45.5		45.5
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Share Price [Member]
Measurement input, embedded derivative	[4]			25.2		25.2
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative				0.801		0.801
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative				0.0488		0.0488
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative				0		0
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Measurement input, embedded derivative				0.8		0.8
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value	[1]			$ 11,600		$ 11,600
Deemed dividend						$ 2,000
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				45.5		45.5
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.801		0.801
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0491		0.0491
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.8		0.8
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value	[1]			$ 6,800		$ 6,800
Deemed dividend						$ 5,100
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				8.75		8.75
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member]
Measurement Input				8.07		8.07
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.793		0.793
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0543		0.0543
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.3		0.3
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member]
Total Value	[1]			$ 900		$ 900
Deemed dividend						$ 400
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				4.9		4.9
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Option Volatility [Member]
Measurement Input				0.799		0.799
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0551		0.0551
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.1		0.1
Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member]
Total value, embedded				$ 200		$ 200
Gain, embedded derivative						$ (82)
Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative				4.9		4.9
Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Share Price [Member]
Measurement input, embedded derivative				4.94		4.94
Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative				0.839		0.839
Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative				0.0494		0.0494
Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative				0		0
Stockholder Approval May 28 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Term [Member]
Measurement input, embedded derivative				1.8		1.8
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member]
Total value, embedded	[3]			$ 200		$ 200
Gain, embedded derivative						$ 40
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative				45.5		45.5
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Share Price [Member]
Measurement input, embedded derivative				23.8		23.8
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative				0.769		0.769
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative				0.0541		0.0541
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative				0		0
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Measurement input, embedded derivative				0.7		0.7
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member]
Total Value				$ 300		$ 300
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				220.5		220.5
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Share Price [Member]
Measurement Input	[5]			25.2		25.2
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.801		0.801
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0359		0.0359
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				1.1		1.1
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0473		0.0473
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Pre-amendment [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				5.6		5.6
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member]
Total Value				$ 500		$ 500
Non-cash gain on changes in fair value of warrant liabilities						$ 200
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				52.5		52.5
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Share Price [Member]
Measurement Input	[5]			25.2		25.2
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.801		0.801
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0359		0.0359
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				1.1		1.1
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0473		0.0473
July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Post-amendment [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				5.6		5.6
The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member]
Total Value				$ 56		$ 56
The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				45.5		45.5
The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Share Price [Member]
Measurement Input				8.07		8.07
The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.793		0.793
The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0392		0.0392
The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				1.5		1.5
The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0462		0.0462
The May 2023 Warrants [Member] | Pre-amendment, December 21, 2023 [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				4.5		4.5
The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member]
Total Value				$ 200		$ 200
Non-cash gain on changes in fair value of warrant liabilities						$ 100
The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				8.75		8.75
The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Share Price [Member]
Measurement Input				8.07		8.07
The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.793		0.793
The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0392		0.0392
The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				1.5		1.5
The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0462		0.0462
The May 2023 Warrants [Member] | Post amendment, December 21, 2023 [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				4.5		4.5
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member]
Total Value				$ 66		$ 66
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Share Price [Member]
Measurement Input				2.51		2.51
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.893		0.893
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Minimum [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				8.75		8.75
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0427		0.0427
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				1		1
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Maximum [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				52.5		52.5
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0508		0.0508
September 2022, November 2022, and May 2023 Warrants [Member] | Pre-amendment June 14, 2024 [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				4.4		4.4
September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member]
Total Value				$ 100		$ 100
Non-cash gain on changes in fair value of warrant liabilities						$ 70
September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				2.5		2.5
September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Share Price [Member]
Measurement Input				2.51		2.51
September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.893		0.893
September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0427		0.0427
September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				1		1
September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0508		0.0508
September 2022, November 2022, and May 2023 Warrants [Member] | Post amendment June 14, 2024 [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				4.4		4.4
Series F-1 Warrants [Member] | Prior to Adjustment [Member]
Total Value				$ 1,700		$ 1,700
Series F-1 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				1.1		1.1
Series F-1 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Share Price [Member]
Measurement Input				0.71		0.71
Series F-1 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.971		0.971
Series F-1 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0355		0.0355
Series F-1 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
Series F-1 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Expected Term [Member]
Measurement Input				4.84		4.84
Series F-1 Warrants [Member] | After Adjustment [Member]
Total Value				$ 1,900		$ 1,900
Deemed dividend						$ 200
Series F-1 Warrants [Member] | After Adjustment [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				0.66		0.66
Series F-1 Warrants [Member] | After Adjustment [Member] | Measurement Input, Share Price [Member]
Measurement Input				0.71		0.71
Series F-1 Warrants [Member] | After Adjustment [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.971		0.971
Series F-1 Warrants [Member] | After Adjustment [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0355		0.0355
Series F-1 Warrants [Member] | After Adjustment [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
Series F-1 Warrants [Member] | After Adjustment [Member] | Measurement Input, Expected Term [Member]
Measurement Input				4.84		4.84
Series F-2 Warrants [Member] | Prior to Adjustment [Member]
Total Value				$ 200		$ 200
Series F-2 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				1.1		1.1
Series F-2 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Share Price [Member]
Measurement Input				0.71		0.71
Series F-2 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.971		0.971
Series F-2 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0464		0.0464
Series F-2 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
Series F-2 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.34		0.34
Series F-2 Warrants [Member] | After Adjustment [Member]
Total Value				$ 600		$ 600
Deemed dividend						$ 400
Series F-2 Warrants [Member] | After Adjustment [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				0.66		0.66
Series F-2 Warrants [Member] | After Adjustment [Member] | Measurement Input, Share Price [Member]
Measurement Input				0.71		0.71
Series F-2 Warrants [Member] | After Adjustment [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.971		0.971
Series F-2 Warrants [Member] | After Adjustment [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0464		0.0464
Series F-2 Warrants [Member] | After Adjustment [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
Series F-2 Warrants [Member] | After Adjustment [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.34		0.34
Series F-3 Warrants [Member] | Prior to Adjustment [Member]
Total Value				$ 600		$ 600
Series F-3 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				1.1		1.1
Series F-3 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Share Price [Member]
Measurement Input				0.71		0.71
Series F-3 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.971		0.971
Series F-3 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.041		0.041
Series F-3 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
Series F-3 Warrants [Member] | Prior to Adjustment [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.84		0.84
Series F-3 Warrants [Member] | After Adjustment [Member]
Total Value				$ 1,000		$ 1,000
Deemed dividend						$ 400
Series F-3 Warrants [Member] | After Adjustment [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				0.66		0.66
Series F-3 Warrants [Member] | After Adjustment [Member] | Measurement Input, Share Price [Member]
Measurement Input				0.71		0.71
Series F-3 Warrants [Member] | After Adjustment [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.971		0.971
Series F-3 Warrants [Member] | After Adjustment [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.041		0.041
Series F-3 Warrants [Member] | After Adjustment [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
Series F-3 Warrants [Member] | After Adjustment [Member] | Measurement Input, Expected Term [Member]
Measurement Input				0.84		0.84
March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member]
Total Value				$ 100		$ 100
Non-cash gain on changes in fair value of warrant liabilities						$ 21
March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				4.9		4.9
March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Share Price [Member]
Measurement Input				3.66		3.66
March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.869		0.869
March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0421		0.0421
March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
March 2024 Warrant [Member] | Reporting Date, March 31, 2024 [Member] | Measurement Input, Expected Term [Member]
Measurement Input				5.5		5.5
March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member]
Total Value				$ 100		$ 100
Non-cash gain on changes in fair value of warrant liabilities						$ (28)
March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				4.9		4.9
March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Share Price [Member]
Measurement Input				4.94		4.94
March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.839		0.839
March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0456		0.0456
March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
March 2024 Warrant [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Expected Term [Member]
Measurement Input				5.3		5.3
May 2023 Warrants [Member]
Non-cash gain on changes in fair value of warrant liabilities		$ (47)	$ (170)
May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member]
Total Value				$ 1,400		$ 1,400
Non-cash gain on changes in fair value of warrant liabilities						$ 200
May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				45.5		45.5
May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Share Price [Member]
Measurement Input				23.8		23.8
May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.776		0.776
May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0392		0.0392
May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				2		2
May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0459		0.0459
May 2023 Warrants [Member] | Stockholder Approval, June 9, 2023 [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				5		5
May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member]
Total Value				$ 1,600		$ 1,600
May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				45.5		45.5
May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Share Price [Member]
Measurement Input	[6]			25.2		25.2
May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.801		0.801
May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.036		0.036
May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				2.1		2.1
May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0404		0.0404
May 2023 Warrants [Member] | Issuance, May 1, 2023 [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Measurement Input				5.1		5.1
The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member]
Total Value				$ 200		$ 200
Non-cash gain on changes in fair value of warrant liabilities						$ (51)
The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				8.75		8.75
The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Share Price [Member]
Measurement Input	[6]			4.94		4.94
The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.839		0.839
The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0456		0.0456
The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
The December 2023 Warrants [Member] | Stockholder Approval May 28 2024 [Member] | Measurement Input, Expected Term [Member]
Measurement Input				5.1		5.1
The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member]
Total Value				$ 300		$ 300
Non-cash gain on changes in fair value of warrant liabilities						$ 56
The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Exercise Price [Member]
Measurement Input				8.75		8.75
The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Share Price [Member]
Measurement Input				7.14		7.14
The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Price Volatility [Member]
Measurement Input				0.793		0.793
The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input				0.0385		0.0385
The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input				0		0
The December 2023 Warrants [Member] | Reporting Date, December 31, 2023 [Member] | Measurement Input, Expected Term [Member]
Measurement Input				5.5		5.5
[1]Includes value of incremental shares underlying preferred stock and adjusted for probability of occurrence.[2]Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above.[3]Adjusted for probability of occurrence.[4]Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above.[5]Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above.[6]Adjusted for the dilutive effect of the 2023 Private Placement. See additional discussion above.

Note 4 - Prepaid Expenses and_3

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Prepaid insurance	$ 73	$ 66
Prepaid dues and subscriptions	63	85
Prepaid taxes	49	83
Prepaid inventory	25	73
Other	116	81
Prepaid expenses from discontinued operations	0	(132)
Total prepaid expenses and other current assets	$ 326	$ 256

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Raw materials and supplies	$ 144	$ 1,027
Finished goods	455	2,477
Less: Reserve for excess and obsolete inventory	(126)	(627)
Inventory, net of reserves, from discontinued operations	0	(2,313)
Total inventory, net	$ 473	$ 564

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Depreciation	$ 9	$ 13	$ 32	$ 39
Disposal Group, Including Discontinued Operation, Depreciation and Amortization	0	$ 0	0	$ 0
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment	$ 0		$ 0		$ 0

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property and equipment, at cost	$ 743	$ 760
Less: accumulated depreciation	(682)	(673)
Total property and equipment, net	61	87
Office and Laboratory Equipment [Member]
Property and equipment, at cost	20	20
Furniture and Fixtures [Member]
Property and equipment, at cost	157	157
Computer Equipment and Software [Member]
Property and equipment, at cost	414	431
Leasehold Improvements [Member]
Property and equipment, at cost	$ 152	$ 152

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Contract liabilities (see Note 14)	$ 751	$ 946
Employee payroll and benefits	288	341
Other	108	229
Accrued liabilities from discontinued operations	0	(347)
Total accrued liabilities	$ 1,147	$ 1,169

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating lease – expense	$ 100	$ 100	$ 300	$ 300
Weighted-average remaining lease term (in years) (Year)	2 years 9 months 18 days	3 years 7 months 6 days	2 years 9 months 18 days	3 years 7 months 6 days
Weighted-average discount rate	5%	5%	5%	5%
Operating lease from discontinued operations – expense	$ 0	$ 30	$ 0	$ 91
Operating lease – included in operating cash flow	117	113	310	301
Operating lease from discontinued operations – included in operating cash flow	$ 0	$ 33	$ 0	$ 97

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
2024	$ 117
2025	439
2026	444
2027	290
Total future minimum lease payments	1,290
Less: Imputed interest	(79)
Total	1,211
Operating lease liabilities	390	$ 368
Operating lease liability- non-current	821	$ 1,108
Total	$ 1,211

Note 9 - Financing Activities (

Note 9 - Financing Activities (Details Textual)								1 Months Ended			3 Months Ended			9 Months Ended
		Jul. 29, 2024 USD ($) shares	Jul. 26, 2024 $ / shares shares	May 30, 2024 $ / shares shares	Mar. 24, 2024 USD ($) shares	May 01, 2023 USD ($) $ / shares shares	Apr. 27, 2023	Jun. 30, 2024 USD ($) shares	Dec. 31, 2023 USD ($) $ / shares shares	May 31, 2023 USD ($) $ / shares	Sep. 30, 2024 USD ($) $ / shares shares		Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2024 USD ($) $ / shares shares		Sep. 30, 2023 USD ($) $ / shares shares	Sep. 27, 2024 $ / shares	Mar. 31, 2024 $ / shares shares	Dec. 31, 2022 $ / shares
Class of Warrant or Right, Issued During Period (in shares)														10,730,589		145,056
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 50.96		$ 1.41		$ 76.23	$ 1.41		$ 76.23			$ 269.54
Class of Warrant or Right, Exercised During Period (in shares)														90,381		0
Modification of Warrants | $														$ 69,000		$ 285,000
Fair Value Adjustment of Warrants | $											$ 0		$ 0	(114,000)		$ (216,000)
The 2024 Warrant Reprice Transaction [Member]
Debt Issuance Costs, Net | $											$ 96,000			$ 96,000
Unsecured Convertible Notes [Member]
Debt Issuance Costs, Net | $					$ 130,000
Debt Instrument, Face Amount | $					$ 525,000
Debt Instrument, Convertible, Number of Equity Instruments				107,146	3,750,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $					$ 19,000
Other Expenses | $					$ 111,000
Original Issue Discount Senior Secured Convertible Debentures [Member]
Debt Issuance Costs, Net | $						$ 300,000
Debt Instrument, Face Amount | $						3,300,000
Debt Instrument, Convertible, Number of Equity Instruments				72,528			2,538,464
Fair Value Adjustment of Warrants | $						40,000
Debt Instrument, Unamortized Discount | $						$ 300,000
Prefunded Warrants 2024 Public Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)			2,041,814											2,041,814
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.01														$ 0.66
Stock Issued In Connection with Exercise of Warrants, Shares (in shares)											2,041,814			2,041,814
Class of Warrant or Right, Exercised During Period (in shares)														2,041,814
Series F-1 Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)			3,200,380
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,200,380
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.1								$ 0.66	[1]		$ 0.66	[1]
Warrants and Rights Outstanding, Term (Year)			5 years
Series F-2 Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)			3,200,380
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,200,380
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.1								$ 0.66	[1]		$ 0.66	[1]
Warrants and Rights Outstanding, Term (Year)											6 months			6 months
Series F-3 Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)			3,200,380
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,200,380
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.1								$ 0.66	[1]		$ 0.66	[1]
Warrants and Rights Outstanding, Term (Year)			1 year
Existing Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 2.5			$ 2.5
Class of Warrant or Right, Exercised During Period (in shares)								90,381
Proceeds from Warrant Exercises | $								$ 200,000
June 2024 Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											90,381			90,381
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	[1]										$ 2.57			$ 2.57
Warrants and Rights Outstanding, Term (Year)											5 years 6 months			5 years 6 months
The 2024 Warrant Reprice Transaction [Member]
Modification of Warrants | $											$ (69)			$ (69)
March 2024 Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				28,572	1,000,000													1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 4.9							$ 4.9	[1]		$ 4.9	[1]			$ 0.14
May 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 8.75						$ 1.3	8.75			8.75
Proceeds from Warrant Exercises | $									$ 200,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $									100,000
Fair Value Adjustment of Warrants | $								$ (47,000)	$ (170,000)
May 2023 Warrants [Member] | Post-split Amount [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares										$ 45.5
The 2023 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				72,256					2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 0.25
Proceeds from Warrant Exercises | $									$ 600,000
Debt Issuance Costs, Net | $									200,000
Other Expenses | $									$ 100,000
The 2023 Warrant Reprice Transaction [Member] | Post-split Amount [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 8.75
The December 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				72,256					2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 8.75					$ 0.25		$ 8.75	[1]		$ 8.75	[1]
Proceeds from Warrant Exercises | $									$ 400,000
The 2023 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				145,056		5,076,928
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 1.5
Fair Value Adjustment of Warrants | $						$ 400,000
The 2024 Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,158,566
Maximum Percentage of Common Stock Outstanding			4.99%
Proceeds from Issuance of Stock and Warrants | $		$ 3,900,000
The 2024 Public Offering [Member] | Election of the holder prior to the date of issuance [Member]
Maximum Percentage of Common Stock Outstanding			9.99%
Over-Allotment Option [Member] | Underwriter From 2024 Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		336,832
Over-Allotment Option [Member] | Maximum Amount Purchasable By Underwriter [Member] | Underwriter From 2024 Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			477,272
Over-Allotment Option [Member] | Series F-1 Warrants [Member] | Underwriter From 2024 Public Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)		336,832
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		336,832
Over-Allotment Option [Member] | Series F-1 Warrants [Member] | Maximum Amount Purchasable By Underwriter [Member] | Underwriter From 2024 Public Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)			477,272
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			477,272
Over-Allotment Option [Member] | Series F-2 Warrants [Member] | Underwriter From 2024 Public Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)		336,832
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		336,832
Over-Allotment Option [Member] | Series F-2 Warrants [Member] | Maximum Amount Purchasable By Underwriter [Member] | Underwriter From 2024 Public Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)			477,272
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			477,272
Over-Allotment Option [Member] | Series F-3 Warrants [Member] | Underwriter From 2024 Public Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)		336,832
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		336,832
Over-Allotment Option [Member] | Series F-3 Warrants [Member] | Maximum Amount Purchasable By Underwriter [Member] | Underwriter From 2024 Public Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)			477,272
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			477,272
The 2023 Private Placement [Member]
Debt Issuance Costs, Net | $						700,000
Other Expenses | $						400,000
Proceeds From Debenture and Warrant Issuances, Net | $						3,000,000
Proceeds from Issuance of Warrants | $						1,600,000
Proceeds from Derivative Instrument, Financing Activities | $										$ 200,000
Proceeds from Convertible Debt | $						1,200,000
The 2023 Private Placement [Member] | Original Issue Discount Senior Secured Convertible Debentures [Member]
Debt Instrument, Unamortized Discount | $						$ 300,000
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 10 - Convertible Notes (De

Note 10 - Convertible Notes (Details Textual)							1 Months Ended	2 Months Ended	3 Months Ended		9 Months Ended
	Jul. 26, 2024 USD ($)	May 30, 2024 $ / shares	Mar. 24, 2024 USD ($) $ / shares	Mar. 01, 2024 USD ($)	May 01, 2023 USD ($)	Apr. 27, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($)	May 28, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Mar. 31, 2024 USD ($)	Jun. 09, 2023 USD ($)
Amortization of Debt Issuance Costs and Discounts									$ 138,000	$ 655,000	$ 871,000	$ 1,156,000
Gain (Loss) on Extinguishment of Debt									(13,000)	0	(13,000)	0
Repayments of Convertible Debt											1,990,000	770,000
Fair Value Adjustment of Warrants									$ 0	$ 0	$ (114,000)	$ (216,000)
The 2023 Private Placement [Member]
Proceeds from Convertible Debt					$ 1,200,000
Debt Issuance Costs, Net					700,000
Unsecured Convertible Notes [Member]
Debt Instrument, Face Amount			$ 525,000
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 4.9	$ 0.14
Debt Instrument, Convertible, Number of Equity Instruments		107,146	3,750,000
Embedded Derivative, Fair Value of Embedded Derivative Liability													$ 159,000
Embedded Derivative, Fair Value								$ 242,000
Unrealized Gain (Loss) on Derivatives								$ 83,000
Debt Instrument, Interest Rate, Effective Percentage									144%		144%
Amortization of Debt Issuance Costs and Discounts									$ 20		$ 35
Debt Issuance Costs, Net			$ 130,000
Original Issue Discount Senior Secured Convertible Debentures [Member]
Debt Instrument, Face Amount					3,300,000
Debt Instrument, Convertible, Conversion Price | $ / shares						$ 1.3
Debt Instrument, Convertible, Number of Equity Instruments		72,528				2,538,464
Embedded Derivative, Fair Value						$ 209,000								$ 169,000
Debt Instrument, Interest Rate, Effective Percentage													173%
Amortization of Debt Issuance Costs and Discounts									12,000,000		$ 800,000
Debt Instrument, Unamortized Discount					300,000
Gain (Loss) on Extinguishment of Debt									$ (13,000)
Debt Instrument, Increase (Decrease), Net						183,000
Debt Instrument, Redemption Price, Amount Per Month						$ 193,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger						90%
Debt Instrument, Convertible, Threshold Trading Days						10
Debt Instrument, Redemption Price, Percentage						20%
Repayments of Convertible Debt	$ 433,000			$ 45,000			$ 126,000
Fair Value Adjustment of Warrants					40,000
Debt Issuance Costs, Net					300,000
Original Issue Discount Senior Secured Convertible Debentures [Member] | The 2023 Private Placement [Member]
Debt Instrument, Unamortized Discount					$ 300,000
Original Issue Discount Senior Secured Convertible Debentures [Member] | Measurement Input, Redemption in Stock [Member]
Debt Instrument, Redemption Price, Amount Per Month						$ 193,000
Original Issue Discount Senior Secured Convertible Debentures [Member] | Post-split Amount [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 45.5				$ 45.5

Note 11 - Common Stock Warran_3

Note 11 - Common Stock Warrants (Details Textual) $ / shares in Units, $ in Thousands							1 Months Ended				3 Months Ended				9 Months Ended
		Jul. 26, 2024 USD ($) $ / shares shares	May 30, 2024 $ / shares shares		May 01, 2023 USD ($) $ / shares shares	Sep. 09, 2022 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) shares	May 31, 2024 shares	Dec. 31, 2023 USD ($) $ / shares shares	May 31, 2023 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares		Jun. 30, 2024 USD ($)	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2024 USD ($) $ / shares shares		Sep. 30, 2023 USD ($) $ / shares shares	Sep. 27, 2024 $ / shares	Mar. 31, 2024 $ / shares shares	Mar. 24, 2024 shares	Dec. 31, 2022 $ / shares	Nov. 10, 2022 $ / shares shares	Nov. 30, 2021 $ / shares shares	Sep. 09, 2020 shares	Jul. 31, 2020 $ / shares shares
Class of Warrant or Right, Issued During Period (in shares)															10,730,589		145,056
Stock Issued In Connection with Exercise of Warrants, Value | $											$ 21		$ 130
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 50.96		$ 1.41			$ 76.23	$ 1.41		$ 76.23				$ 269.54
Class of Warrant or Right, Exercised During Period (in shares)															90,381		0
Fair Value Adjustment of Warrants | $											$ 0			$ 0	$ 114		$ 216
Class of Warrant or Right, Forfeited During Period															14,879		0
Fair Value Adjustment of Warrants | $											$ 0			$ 0	$ (114)		$ (216)
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			35	[1]							35
Prefunded Warrants 2024 Public Offering [Member]
Class of Warrant or Right, Issued During Period (in shares)		2,041,814													2,041,814
Stock Issued In Connection with Exercise of Warrants, Shares (in shares)											2,041,814				2,041,814
Stock Issued In Connection with Exercise of Warrants, Value | $		$ 20
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.01																$ 0.66
Class of Warrant or Right, Exercised During Period (in shares)															2,041,814
The July 2024 Series F-1 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,537,212
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 1.1
The July 2024 Series F-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,537,212
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 1.1
The July 2024 Series F-3 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,537,212
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 1.1
The July 2024 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																		$ 0.66
Adjustment to Warrant Exercise Price, Deemed Dividend | $															$ 1,000
June 2024 Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											90,381				90,381
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	[2]										$ 2.57				$ 2.57
March 2024 Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			28,572																1,000,000	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 4.9								4.9	[2]			4.9	[2]			$ 0.14
The December 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			72,256						2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 8.75						$ 0.25		8.75	[2]			8.75	[2]
The May 2023 B-1 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			72,528							2,538,464
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 45.5						$ 1.3	$ 1.3
Class of Warrant or Right, Exercised During Period (in shares)			18,132				54,396		634,616
The May 2023 B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			72,528							2,538,464
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 45.5							$ 1.3
Class of Warrant or Right, Exercised During Period (in shares)			54,120				18,408		1,894,232
May 2023 Warrants Amended By 2023 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 0.25
May 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 8.75							$ 1.3	8.75				8.75
Fair Value Adjustment of Warrants | $							$ 47		$ 170
Fair Value Adjustment of Warrants | $							(47)		$ (170)
May 2023 Warrants Amended By 2024 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 2.5				$ 2.5
The November 2022 A-1 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			14,741							436,510	12,473				12,473							515,876
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 220.5							$ 52.5	$ 220.5	[2]			$ 220.5	[2]						$ 6.3
The November 2022 A-1 Warrants [Member] | Post-amendment [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			12,473
The November 2022 A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			14,741							436,510												515,876
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 220.5																			$ 6.3
Class of Warrant or Right, Forfeited During Period								14,741
The November 2022 A-2 Warrants [Member] | Post-amendment [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			12,473
The November 2022 A-1 and A-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 220.5							$ 6.3
The Amended November 2022 A-1 and A-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 52.5							$ 1.5
Fair Value Adjustment of Warrants | $							(16)			$ (74)
Fair Value Adjustment of Warrants | $							16			$ 74
November 2022 Warrants Amended By 2024 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 2.5				$ 2.5
The 2022 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			9,371			327,860
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 220.5			$ 6.3
September 2022 Warrants Amended in 2023 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			6,819							238,574
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 52.5			52.5				$ 1.5
September 2022 Warrants Amended in 2024 Warrant Reprise Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											5,104				5,104
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 2.5				$ 2.5
September 2022 Warrants Amended [Member]
Fair Value Adjustment of Warrants | $							(6)			$ (28)
Fair Value Adjustment of Warrants | $							$ 6			$ 28
The November 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			30,616		535,716																		1,071,434
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 649.25								220.5	[2]			220.5	[2]							$ 18.55
Amended November 2021 Warrants Exercisable for 6.50 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 220.5		$ 6.3	$ 6.3
Class of Warrant or Right, Exercised During Period (in shares)						7,654
Fair Value Adjustment of Warrants | $						$ (1,500)
Fair Value Adjustment of Warrants | $						$ 1,500
November 2021 Warrants Adjusted From 2023 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			15,308
Amended November 2021 Warrants Exercisable for 1.50 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 52.5		$ 1.5
Fair Value Adjustment of Warrants | $					$ (100)
Fair Value Adjustment of Warrants | $					$ 100
The July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			5,635																						197,105
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 2,021.25								$ 2,021.25	[2]			$ 2,021.25	[2]									$ 57.75
Amended July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					77,145						3,921				3,921									137,145
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 220.5		$ 6.3	$ 6.3
Fair Value Adjustment of Warrants | $					$ (9,000)	$ (400)
Fair Value Adjustment of Warrants | $					$ 9,000	$ 400
The Amended July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			2,206
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 52.5								$ 52.5	[2]			$ 52.5	[2]
The 2023 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			145,056		5,076,928
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 1.5
Fair Value Adjustment of Warrants | $					$ (400)
Fair Value Adjustment of Warrants | $					$ 400
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.[2]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 11 - Common Stock Warran_4

Note 11 - Common Stock Warrants - Outstanding Warrants (Details) - $ / shares		9 Months Ended
	Jul. 26, 2024	Sep. 30, 2024		Sep. 30, 2023
Outstanding warrants (in shares)		210,946		65,886
Outstanding warrants, weighted-average exercise price (in dollars per share)		$ 50.96		$ 269.54
Warrants granted (in shares)		10,730,589		145,056
Warrants granted, weighted average exercise price (in dollars per share)		$ 0.69		$ 45.5
Warrants exercised (in shares)		90,381		0
Warrants exercised, weighted-average exercise price (in dollars per share)		$ 2.5		$ 0
Warrants expired (in shares)		(14,879)		0
Warrants expired, weighted average exercise price (in dollars per share)		$ 88.87		$ 0
Warrants exercised (in shares)		(90,381)		0
Outstanding warrants (in shares)		10,836,275	[1]	210,942
Outstanding warrants, weighted-average exercise price (in dollars per share)		$ 1.41		$ 76.23
Prefunded Warrants 2024 Public Offering [Member]
Warrants granted (in shares)	2,041,814	2,041,814
Warrants granted, weighted average exercise price (in dollars per share)		$ 0.01
Warrants exercised (in shares)		2,041,814
Warrants exercised, weighted-average exercise price (in dollars per share)		$ 0.01
Warrants exercised (in shares)		(2,041,814)
Outstanding warrants, weighted-average exercise price (in dollars per share)	$ 0.01
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 11 - Common Stock Warran_5

Note 11 - Common Stock Warrants - Warrants Outstanding (Details) - $ / shares

Sep. 30, 2024

Jul. 26, 2024

May 30, 2024

Mar. 31, 2024

Dec. 31, 2023

Sep. 30, 2023

May 31, 2023

Dec. 31, 2022

Nov. 10, 2022

Nov. 30, 2021

Jul. 31, 2020

Exercise price (in dollars per share)

$ 1.41

$ 50.96

$ 76.23

$ 269.54

Warrants outstanding (in shares)

10,836,275

[1]

210,946

210,942

65,886

The July 2020 Warrants [Member]

Exercise price (in dollars per share)

$ 2,021.25

[1]

$ 2,021.25

$ 57.75

Expiration date

Jan. 22, 2026

Warrants outstanding (in shares)

[1]

1,714

The Amended July 2020 Warrants [Member]

Exercise price (in dollars per share)

$ 52.5

[1]

52.5

Expiration date

Jan. 22, 2026

Warrants outstanding (in shares)

[1]

2,206

TLF Bio Innovation 2021 Warrants [Member]

Exercise price (in dollars per share)

[1]

$ 822.96

Expiration date

Jan. 15, 2026

Warrants outstanding (in shares)

[1]

13

The November 2021 Warrants [Member]

Exercise price (in dollars per share)

$ 220.5

[1]

649.25

$ 18.55

Expiration date

Sep. 11, 2028

Warrants outstanding (in shares)

[1]

7,654

The Amended November 2021 Warrants [Member]

Exercise price (in dollars per share)

[1]

$ 52.5

Expiration date

Sep. 11, 2028

Warrants outstanding (in shares)

[1]

15,308

The September 2022 Warrants [Member]

Exercise price (in dollars per share)

[1]

$ 220.5

Expiration date

Sep. 11, 2028

Warrants outstanding (in shares)

[1]

2,552

The Amended September 2022 Warrants [Member]

Exercise price (in dollars per share)

[1]

$ 52.5

Expiration date

Sep. 11, 2028

Warrants outstanding (in shares)

[1]

1,715

The November 2022 A-1 Warrants [Member]

Exercise price (in dollars per share)

$ 220.5

[1]

220.5

$ 52.5

$ 6.3

Expiration date

Nov. 20, 2028

Warrants outstanding (in shares)

[1]

2,268

The December 2023 Warrants [Member]

Exercise price (in dollars per share)

$ 8.75

[1]

8.75

$ 0.25

Expiration date

Jun. 21, 2029

Warrants outstanding (in shares)

[1]

72,256

March 2024 Warrant [Member]

Exercise price (in dollars per share)

$ 4.9

[1]

$ 4.9

$ 0.14

Expiration date

Mar. 24, 2029

Warrants outstanding (in shares)

[1]

28,572

June 2024 Warrant [Member]

Exercise price (in dollars per share)

[1]

$ 2.57

Expiration date

Dec. 17, 2029

Warrants outstanding (in shares)

[1]

90,381

Series F-1 Warrants [Member]

Exercise price (in dollars per share)

$ 0.66

[1]

$ 1.1

Expiration date

Jul. 30, 2029

Warrants outstanding (in shares)

[1]

3,537,212

Series F-2 Warrants [Member]

Exercise price (in dollars per share)

$ 0.66

[1]

1.1

Expiration date

Jan. 29, 2025

Warrants outstanding (in shares)

[1]

3,537,212

Series F-3 Warrants [Member]

Exercise price (in dollars per share)

$ 0.66

[1]

$ 1.1

Expiration date

Jul. 29, 2025

Warrants outstanding (in shares)

[1]

3,537,212

[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 11 - Common Stock Warran_6

Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details) - Warrant Liability [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Warrant liabilities	$ 334
Warrant liabilities	0
The December 2023 Warrants [Member]
Change in fair value of warrant liability during period	(122)
Reclassification of warrant liability to equity during period	(212)
March 2024 Warrant [Member]
Change in fair value of warrant liability during period	8
Fair value of March 2024 Warrant upon issuance	92
Reclassification of warrant liability to equity during period	$ (100)

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Millions								1 Months Ended	3 Months Ended
	May 30, 2024	[1]	Mar. 27, 2024 shares	Dec. 21, 2023 USD ($) $ / shares	Apr. 27, 2023 USD ($) $ / shares	Sep. 09, 2022 USD ($) $ / shares shares	Oct. 29, 2021 shares	Mar. 31, 2024 USD ($) $ / shares	Sep. 30, 2024 $ / shares shares	May 27, 2024	Apr. 27, 2024 $ / shares	Jan. 29, 2024 $ / shares	Dec. 31, 2023 shares	Sep. 30, 2023 $ / shares shares
Common Stock, Shares Authorized (in shares) | shares									150,000,000				150,000,000
Preferred Stock, Shares Authorized (in shares) | shares									5,000,000				5,000,000
Preferred Stock, Convertible, Shares Issuable (in shares) | shares									1,000
Preferred Stock, Shares Outstanding (in shares) | shares									0				1
May 2023 Warrants [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)					$ 1.3
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding (in shares) | shares									1,000				6,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)					$ 6.3							$ 0.25
Preferred Stock, Change in Conversion Price, Income Statement Impact | $				$ 4.5		$ 5.7
Series B Preferred Stock [Member] | Minimum [Member]
Preferred Stock, Convertible, Conversion Ratio												75
Series B Preferred Stock [Member] | Previously Reported [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)				$ 1.3		$ 14
Series B Preferred Stock [Member] | Revision of Prior Period, Adjustment [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)				0.25		6.3
Series B Preferred Stock [Member] | The 2021 Private Placement Program [Member]
Preferred Stock, Convertible, Shares Issuable (in shares) | shares									527,275					4,735,500
Stock Issued During Period, Shares, New Issues (in shares) | shares							15,000
Preferred Stock, Shares Outstanding (in shares) | shares									131					6,150
Preferred Stock, Convertible, Conversion Price (in dollars per share)									$ 0.25					$ 1.3
Series B Preferred Stock [Member] | The 2023 Private Placement [Member]
Preferred Stock, Change in Conversion Price, Income Statement Impact | $					$ 1.8
Series B Preferred Stock, Post-split [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)												$ 8.75
Series B Preferred Stock, Post-split [Member] | Previously Reported [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)				45.5	$ 220.5	490
Series B Preferred Stock, Post-split [Member] | Revision of Prior Period, Adjustment [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)				$ 8.75	45.5	$ 220.5
Series B Preferred Stock, Post-split [Member] | The 2021 Private Placement Program [Member]
Preferred Stock, Convertible, Shares Issuable (in shares) | shares									15,065					135,300
Preferred Stock, Convertible, Conversion Price (in dollars per share)									$ 8.75					$ 45.5
Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares			3,250
Preferred Stock, Change in Conversion Price, Income Statement Impact | $				$ 0.5				$ 0.4
Series C Preferred Stock [Member] | Minimum [Member]
Preferred Stock, Convertible, Conversion Ratio										75
Series C Preferred Stock [Member] | Previously Reported [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)				$ 1.3	6.3			$ 0.25
Series C Preferred Stock [Member] | Revision of Prior Period, Adjustment [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)				0.25	$ 1.3			0.14
Series C Preferred Stock [Member] | The 2023 Private Placement [Member]
Preferred Stock, Change in Conversion Price, Income Statement Impact | $					$ 194
Series C Preferred Stock [Member] | The 2022 Private Placement [Member]
Preferred Stock, Convertible, Shares Issuable (in shares) | shares														844,690
Stock Issued During Period, Shares, New Issues (in shares) | shares						3,250
Preferred Stock, Shares Outstanding (in shares) | shares									0					1,097
Preferred Stock, Convertible, Conversion Price (in dollars per share)														$ 1.3
Series C Preferred Stock, Post-split [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)					$ 220.5
Series C Preferred Stock, Post-split [Member] | Previously Reported [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)				45.5				8.75
Series C Preferred Stock, Post-split [Member] | Revision of Prior Period, Adjustment [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)				$ 8.75				$ 4.9			$ 45.5
Series C Preferred Stock, Post-split [Member] | The 2022 Private Placement [Member]
Preferred Stock, Convertible, Shares Issuable (in shares) | shares														24,134
Preferred Stock, Convertible, Conversion Price (in dollars per share)														$ 45.5
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	35								35
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 13 - Equity-based Compen_3

Note 13 - Equity-based Compensation (Details Textual) $ in Thousands				1 Months Ended		3 Months Ended		9 Months Ended
	May 30, 2024	[1]	Mar. 31, 2023 shares	Mar. 31, 2017 shares	Oct. 31, 2007	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)						0	0	0	0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $						$ 100		$ 100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)								1 year 3 months 18 days
Share-Based Payment Arrangement, Expense | $						$ 22	$ 62	$ 137	$ 201
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)							36,000		36,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						0	0	0
Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)								0	6,150
Employees and Directors [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									5,148
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	35					35
Restricted Stock [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)							0
Share-Based Payment Arrangement, Expense | $						$ 0	$ 3	$ 13	$ 7
Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						0
Restricted Stock [Member] | Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)								5,148,000
Share-Based Payment Arrangement, Expense | $						$ 22	$ 59	$ 124	$ 194
Post-split Amount [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)									1,032
Post-split Amount [Member] | Employees and Directors [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									150
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)					10 years
The 2017 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				66,243
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock				4%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)			12,219
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)						13,650		13,650
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum				10%
The 2017 Omnibus Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				4 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)				10 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)				5 years
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent				100%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent				110%
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 13 - Equity-based Compen_4

Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) $ / shares in Units, $ in Thousands			9 Months Ended		12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares		Sep. 30, 2024 USD ($) $ / shares shares		Dec. 31, 2023 USD ($) $ / shares shares
Outstanding awards (in shares)			4	[1]
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares			$ 1,145.87	[1]
Outstanding, weighted-average remaining contractual life (Year)			8 years 6 months		7 years 3 months 18 days
Outstanding, aggregate intrinsic value | $	$ 4		$ 4		$ 1
Options forfeited/cancelled (in shares)			(2)	[1]
Options forfeited/cancelled, weighted-average exercise price (in dollars per share) | $ / shares			$ 535.07	[1]
Outstanding awards (in shares)	7	[1]	7	[1]	4	[1]
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 470.76	[1]	$ 470.76	[1]	$ 1,145.87	[1]
Vested and expected to vest (in shares)	7	[1]	7	[1]
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares	$ 474.75	[1]	$ 474.75	[1]
Vested and expected to vest at March 31, 2024Vested and expected to vest, weighted-average remaining contractual life (Year)			8 years 6 months
Vested and expected to vest, aggregate intrinsic value | $	$ 4		$ 4
Vested and exercisable (in shares)	1	[1]	1	[1]
Exercisable, weighted-average exercise price (in dollars per share) | $ / shares	$ 2,122.83	[1]	$ 2,122.83	[1]
Exercisable, weighted-average remaining contractual life (Year)			4 years 8 months 12 days
Restricted Stock Units (RSUs) [Member]
Restricted stock units granted (in shares)	5	[1]
[1]After giving retroactive effect to the 1-for-35 Reverse Stock Split that became effective May 30, 2024.

Note 13 - Equity-based Compen_5

Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares
Expected price volatility	152.99%
Expected term (in years) (Year)	6 years 9 months 21 days
Risk-free interest rate	3.47%
Dividend yield	0%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 58.57

Note 13 - Equity-based Compen_6

Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock-based compensation expense	$ 22	$ 62	$ 137	$ 201
Research and Development Expense [Member]
Stock-based compensation expense	3	5	12	16
Selling and Marketing Expense [Member]
Stock-based compensation expense	8	18	48	49
General and Administrative Expense [Member]
Stock-based compensation expense	$ 11	$ 39	$ 77	$ 136

Note 14 - Distribution Agreem_3

Note 14 - Distribution Agreements (Details Textual) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenue from Contract with Customer, Including Assessed Tax	$ 2,441,000		$ 2,481,000		$ 7,472,000	$ 8,354,000
Contract with Customer, Liability	751,000				751,000		$ 728,000
DERMAdoctor [Member] | Costco and Others [Member]
Revenue from Contract with Customer, Including Assessed Tax	153,000		$ 232,000		385,000	519
Contract with Customer, Liability	$ 800,000				800,000		$ 700,000
Avenova Direct [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 1,800,000		$ 1,600,000	$ 5,400,000	$ 4,500,000

Note 14 - Distribution Agreem_4

Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Balance at December 31, 2023	$ 946
Less discontinued operations	(218)
Continuing operations balance at December 31, 2023	728
Current period	152
Payments and customer credits issued	(129)
Balance	751
Chargebacks, Discounts for Prompt, Payment, and Other [Member]
Balance at December 31, 2023	913
Less discontinued operations	(218)
Continuing operations balance at December 31, 2023	695
Current period	39
Payments and customer credits issued	(14)
Balance	720
Other Customer Fees [Member]
Balance at December 31, 2023	12
Less discontinued operations	0
Continuing operations balance at December 31, 2023	12
Current period	36
Payments and customer credits issued	(36)
Balance	12
Rebates [Member]
Balance at December 31, 2023	21
Less discontinued operations	0
Continuing operations balance at December 31, 2023	21
Current period	77
Payments and customer credits issued	(79)
Balance	$ 19

Note 15 - Employee Benefit Pl_2

Note 15 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
The 401K Plan Contribution Level One [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			100%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay			3%
The 401K Plan Contribution Level Two [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			50%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay			2%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 24	$ 24	$ 73	$ 70
Disposal Group, Including Discontinued Operations, Defined Contribution Plan, Employer Discretionary Contribution Amount		$ 8		$ 25

Note 16 - Related Party Trans_3

Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Cost of goods sold	$ 848	$ 819	$ 2,493	$ 3,353
Related Party [Member]
Revenue	0	0	0	1,043
Cost of goods sold	$ 0	$ 28	$ 0	$ 923

Note 17 - Segment Reporting (De

Note 17 - Segment Reporting (Details Textual)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Number of Reportable Segments	1	2

Note 18 - Divestiture and Dis_3

Note 18 - Divestiture and Discontinued Operations (Details Textual) - USD ($) $ in Thousands		9 Months Ended
	Mar. 25, 2024	Sep. 30, 2024	Sep. 30, 2023
Proceeds from Divestiture of Businesses		$ 1,070	$ 0
Discontinued Operations, Disposed of by Sale [Member] | DERMAdoctor [Member]
Disposal Group, Including Discontinued Operation, Percentage Sold	100%
Proceeds from Divestiture of Businesses	$ 1,100

Note 18 - Divestiture and Dis_4

Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Cash and cash equivalents	$ 0		$ 0		$ 206,000
Net loss from discontinued operations	0	$ (404,000)	(124,000)	$ (1,106,000)
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023)	0		0		2,313,000
Non-cash right-of-use amortization			254,000	222,000
Prepaid expenses and other current assets	0		0		132,000
Total current assets, discontinued operations	0		0		2,730,000
Accounts receivable			24,000	(913,000)
Total assets, discontinued operations	0		0		19,000
Inventory			83,000	(195,000)
Accrued liabilities	0		0		347,000
Prepaid expenses and other current assets			(70,000)	82,000
Total current liabilities, discontinued operations	0		0		698,000
Other assets			(16,000)	(10,000)
Accounts payable and accrued liabilities			(532,000)	(1,289,000)
Operating lease liabilities			(265,000)	(224,000)
Net loss from discontinued operations	$ 0	$ (404,000)	(124,000)	(1,106,000)
Purchases of property and equipment			(6,000)	(16,000)
DERMAdoctor [Member] | Discontinued Operations, Disposed of by Sale [Member]
Cash and cash equivalents					206,000
Product revenue, net			717,000	2,645,000
Net loss from discontinued operations			(124,000)	(1,106,000)
Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023)					79,000
Amortization of intangible assets			0	114,000
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023)					2,313,000
Cost of goods sold			493,000	1,566,000
Non-cash right-of-use amortization			0	83,000
Prepaid expenses and other current assets					132,000
Total current assets, discontinued operations					2,730,000
Gross profit			224,000	1,079,000
Accounts receivable			(262,000)	144,000
Other assets					19,000
Total assets, discontinued operations					2,749,000
Research and development			2,000	28,000
Inventory			183,000	139,000
Accounts payable					224,000
Accrued liabilities					347,000
Sales and marketing			292,000	1,413,000
Prepaid expenses and other current assets			(4,000)	146,000
Operating lease liabilities					127,000
Total current liabilities, discontinued operations					698,000
General and administrative			48,000	749,000
Other assets			15,000	(8,000)
Total liabilities, discontinued operations					$ 698,000
Total operating expenses			342,000	2,190,000
Accounts payable and accrued liabilities			63,000	299,000
Operating loss			(118,000)	(1,111,000)
Operating lease liabilities			(31,000)	(89,000)
Other expense, net			(6,000)
Net cash used in operating activities, discontinued operations			(160,000)	(278,000)
Disposal Group, Including Discontinued Operation, Interest Income				(5)
Net loss from discontinued operations			(124,000)	(1,106,000)
Cash transferred to New Age Investments, LLC			(46,000)	0
Purchases of property and equipment			0	(1,000)
Net cash used in investing activities, discontinued operations			(46,000)	(1,000)
Net decrease in cash and cash equivalents, discontinued operations			$ (206,000)	$ (279,000)

Note 18 - Divestiture and Dis_5

Note 18 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals) - DERMAdoctor [Member] - Discontinued Operations, Disposed of by Sale [Member] $ in Thousands	Dec. 31, 2023 USD ($)
Allowance for credit losses	$ 0
Reserve	$ 363

Note 19 - Subsequent Events (De

Note 19 - Subsequent Events (Details Textual) - USD ($) $ in Millions	Nov. 05, 2024	Sep. 19, 2024	Sep. 17, 2024	Sep. 16, 2024
Original Purchase Agreement [Member]
Asset Acquisition, Price of Acquisition, Expected		$ 9.5	$ 9.5	$ 9.5
Subsequent Event [Member] | Bridge Loan [Member]
Debt Instrument, Face Amount	$ 1
Debt Instrument, Interest Rate, Stated Percentage	10%
Debt Instrument, Interest Rate Increased Percentage	12%
Subsequent Event [Member] | Bridge Loan [Member] | Tranche One, Bridge Loan [Member]
Debt Instrument, Funded Amount	$ 0.5
Subsequent Event [Member] | Bridge Loan [Member] | Tranche Two, Bridge Loan [Member]
Debt Instrument, Funded Amount	0.5
Subsequent Event [Member] | APA Amendment [Member]
Asset Acquisition, Price of Acquisition, Expected	$ 11.5